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Abstract
Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder 
caused by mutations in the NF1 gene. Mutation detection in NF1 has been a major 
challenge due to the large size of the gene and lack of mutational hotspots. This study 
reports mutation screening of 91 subjects fulfilling NIH NF1 diagnostic criteria in which 
a mutation detection rate of 89% was achieved using automated comparative sequence 
analysis (ACSA) and many novel mutations are reported. This detection rate makes this 
single technique appropriate for routine clinical practice. The data confirms that 
mutations are evenly distributed along the coding sequence of the NF1 gene and the 
presence of a second putative functional domain upstream of the GRD at exons 11-17. A 
related disorder is also studied: Neurofibromatosis-Noonan syndrome and found to be a 
subtype of NF1 with mutations in the NF1 gene.
Abnormalities of pre-mRNA splicing represent an important mechanism by which gene 
mutations cause disease. Effects on splicing can be predicted from genomic DNA 
sequence analysis if mutations alter highly conserved canonical splicing signals. 
However, it is extremely difficult to predict the effects of changes in intronic and exonic 
sequences not obviously involved in the splicing process. The significance of point 
mutations, including missense and silent changes are difficult to clarify. This study 
presents an efficient and simple test using genomic DNA to construct a minigene and 
analyse the effect on splicing of sequence variations in NFL In particular two mutations 
are described: an intronic mutation that perturbs NF1 gene splicing and can be rescued by 
coexpression of an altered U1 snRNA that restores normal base pairing, and a nonsense 
mutation that interrupts an exonic splice enhancer.
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INTRODUCTION
1. Neurofibromatosis type 1
1.1 Clinical Features o f Neurofibromatosis type 1 (NF1)
Neurofibromatosis type 1 (NF1), formerly known as Von Recklinghausen
Neurofibromatosis is a common genetic disorder affecting approximately 1 per 3000- 
5000 people. It is a fully penetrant autosomal dominant disorder and is defined by strict 
diagnostic criteria, as established by the National Institute of Health (NIH) Consensus 
Conference in 1987 (NIH, 1987). However, clinical descriptions of possible NF1 patients 
date from as early as the 13th century (Mulvihill, 1988). There is wide variability of 
clinical manifestations, many causing considerable morbidity and even mortality. 
Approximately half of all NF1 patients represent de novo cases (Huson et al., 1989).
The diagnostic criteria for NF1 formulated by the National Institutes of Health Consensus 
Development Conference Statement Neurofibromatosis include the following major 
disease features which are predominantly of neural crest origin: cafe-au-lait spots, 
freckling in the axillary or inguinal regions, neurofibromas, Lisch nodules, optic pathway 
glioma, distinctive osseous lesions (sphenoid dysplasia, thinning of long bone cortex with 
or without bowing and pseudarthrosis) and a positive family history of NF1. Two or more 
criteria are necessary for a diagnosis of NF1- Table 1. Most major disease features appear 
with increasing age, nevertheless, diagnosis should be possible by the age of 5 years 
when the penetrance of the disease is considered virtually 100% (Huson et al 1989).
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Table 1
Diagnostic criteria for Neurofibromatosis type 1 (NF1)
2 or more criteria are necessary for a diagnosis of NF1
• 6 or more cafe-au-lait spots over 5mm in greatest diameter in prepubertal individuals 
and over 15mm in greatest diameter in postpubertal individuals
• two or more neurofibromas of any type or one or more plexiform neurofibromas
• freckling in the axillary or inguinal region
• two or more Lisch nodules (iris hamartomas)
• optic or chiasma glioma
• a distinctive osseus lesion, such as sphenoid dysplasia or thinning of long bone 
cortex, with or without bowing or pseudarthrosis
• a first degree relative with NF1 according to the above criteria
Cafe-au-lait spots are generally the first presenting sign of NF1 and are observed in 82% 
of NF1 affected children before the end of the first year (Huson et a l, 1989). In adults 
Cafe-au-lait spots tend to become less pronounced and may even disappear (Figure 1) 
(Huson et al, 1988; Riccardi, 1992). Skin fold freckling of the axillae or groin is often the 
next presenting major disease feature and is observed in 81% of children before 6 years 
of age (Obringer et a l, 1989). Skin fold freckling may also be encountered in the nape of 
the neck, under the chin and in the female submammary region (Gutmann et a l, 1997).
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Neurofibromas are divided into two major types: dermal and plexiform neurofibromas. 
Both types consist of a mixture of Schwann cells, perineural fibroblasts, endothelial cells 
and mast cells. Dermal neurofibromas are cutaneous or subcutaneous tumours, which 
originate from terminal nerve branches in the skin- Figure 2. They start to appear prior to 
puberty and mainly develop on the trunk. They are rarely painful but may cause pruritus 
and can become a major cosmetic burden (Huson, et al 1989). Plexiform neurofibromas 
originate from major nerve plexuses and major peripheral nerves, and as a consequence 
may cause severe complications. They are present in approximately one third of the NF1 
population and are congenital, although they may present later due to growth (Riccardi, 
1992). The overlying skin may be abnormal with either signs of hypertrophy, 
hyperpigmentation or hypertrichosis. Two types of plexiform neurofibromas have been 
described (Huson, 1994). Diffuse plexiform neurofibromas are soft subcutaneous 
swellings with ill-defined margins. Nodular plexiform neurofibromas are ovoid or 
spherically shaped, feel firm and are well circumscribed.
Lisch nodules are small pigmented hamartomas of the iris. They are present in 92% of 
NF1 patients older than 6 years of age (Huson et al 1989). As a consequence these iris 
hamartomas are of great diagnostic importance for NF1.
18
Figure 1 Cafe-au-lait macules
Figure 2 Multiple neurofibromas
19
Optic pathway gliomas or pilocytic astrocytomas of the optic pathway are an important 
complication of NF1 in childhood occurring in 19% of cases (median age of presentation 
of symptomatic tumours: 4.9 years) (Listemick et al., 1994). Generally optic gliomas 
associated with NF1 are less progressive than in children without NF1. Symptomatic 
optic pathway gliomas seldomly appear after 6 years of age. Routine screening with MRI 
imaging of 176 children showed optic glioma in 33 (19%). However only half of these 
children developed glioma-associated signs or symptoms.
Osseous lesions which are particular features of NF1 are sphenoid wing dysplasia and 
congenital bowing or thinning of long cortical bones with or without pseudarthrosis. 
Sphenoid wing dysplasia is rare in NF1 patients but occasionally presents with pulsatile 
exophthalmus. Congenital bowing generally occurs anterolaterally and is located in the 
tibia or fibula in 3% of NF1 patients (Huson, et al 1989). However, NF1 has been 
implicated in more than half of cases of congenital pseudarthrosis of the tibial bone.
The following signs are also frequently observed in NF1 patients: macrocephaly, short 
stature, hypertelorism, thorax abnormalities, scoliosis, precocious puberty, hypertension 
and various learning-, speech-, motor- and behavioural difficulties. These are considered 
minor features of the disease (Huson, et al 1989).
Learning disabilities are observed in 30-45% of NF1 patients (North et al., 1995). 
Cognitive problems include lower full scale IQ, multidimensional cognitive deficits, 
reading disabilities and neuromotor deficits. Speech and behavioural problems are 
frequently seen but are not specific. A less common severe complication of NF1 is mental
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retardation with prevalence between 4.8% and 8% (North et a l , 1994). The aetiology of 
cognitive impairment in NF1 has not been established. An early pathological study 
addressed its anatomical basis and postulated that neurocognitive deficit is due to 
migrational abnormalities in the developing brain (Rosman and Pearce, 1967). 
Hyperintense lesions on T2-weighted brain MRI occur in about 60% of children with 
NF1, but they tend to disappear in adulthood and are seldom observed in patients over 30 
years of age. The lesions do not cause overt neurological symptoms. The nature of these 
lesions is uncertain but it has been postulated that they may represent areas of dysplastic 
glial proliferation and aberrant myelination (DiMario et al., 1993).
In addition there is a lifelong increased risk of some malignancies. Although some 
cancers, notably neurosarcomas, CNS tumours and phaeochromocytoma are known to 
occur with increased frequency in NF1 patients, it is unclear whether there is an increased 
risk of other cancers.
Other subtypes, or related disorders also exist, these include segmental (or mosaic) NF1, 
autosomal dominant cafe-au lait spots alone, Watson syndrome, Neurofibromatosis- 
Noonan syndrome (discussed in section 1.3.1), familial spinal neurofibromatosis, familial 
gastrointestinal neurofibromatosis (Carey, et al 1999). It is unclear whether these are 
disorders with mutations in the NF1 gene or distinct clinical entities.
In summary, complications of NF1 may occur in many different organs and may cause 
severe morbidity or mortality. The course of the disease is unpredictable with intra- and 
inter- familial variability. In addition there is a significant number of patients who have a 
clinical picture suspicious of NF1 but do not fulfil the diagnostic criteria (personal
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experience). As a consequence, diagnosis can be difficult and the availability of accurate 
and rapid genetic testing would have a major impact on the management of these patients 
and families.
1.2 Neurofibromatosis type 1 gene and its product
The NF1 gene was mapped to chromosome 17qll.2 and is thought to be a tumour 
suppressor gene because loss of heterozygosity is associated with the occurrence of 
benign and malignant tumours in neural crest tissues (Colman et al., 1995; Legius et al., 
1992; Serra et al, 1997) as well as myeloid malignancies (Shannon et al., 1994). It spans 
a region of about 350kb of genomic DNA and contains 60 exons (Cawthon et al., 1990; 
Viskochil et al., 1993; Wallace et a l, 1990). It harbours at least three other embedded 
genes - EV12A, EV12B and ONGP, transcribed from the opposite strand of NFJ intron 
27b. The NFJ gene transcribes several mRNAs in the size range ll-13kb- the three 
known alternatively spliced exons are 9a, 23a and 48a; these are expressed ubiquitously 
but more so in the neurons, oligodendrocytes and non-myelinating Schwann cells (Daston 
et a l, 1992). The most common transcript codes for a polypeptide of 2,818 amino acids 
called neurofibromin (Danglot et al., 1995; Li et al, 1995; Marchuk et a l, 1991). The 
protein is 280kD (DeClue et a l, 1991) and has been found in all tissues and cell lines 
examined and has been detected in human, rat and mouse tissues (Gutmann et al, 1991).
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1.2.1 Neurofibromin function
A 360 amino acid region of the predicted protein product, neurofibromin, shows 
homology to the GTPase activating (GAP) family of proteins in yeast (IRA1 and IRA2) 
and mammals (Buchberg et al., 1990; Tanaka et al., 1991; Xu et al., 1990). Until recently 
this was the only known functional domain of the NF1 gene (GRD, GAP-related domain) 
and spans exons 20-27a (bases 3497-4661). It was found to interact with p21ras and GTP 
(Martin et al., 1990) and is thought to downregulate the Ras pathway and prevent 
uncontrolled cell proliferation by converting active Ras GTP (guanosine triphosphatase) 
to inactive RasGDP. In keeping with this, RasGTP levels may be elevated in human NF1 
peripheral nerve tumours in which neurofibromin is reduced or absent (Guha et al.,
1996). This region of the gene also represents a 'hot spot' for mutations consistent with an 
important functional role (Upadhyaya et al., 1997). The primary sequence of the GRD 
shares homology with other known GAPs, especially with the more closely related NF1 
GAPs found in yeasts (IRA1 and IRA2) and Drosophila. The most widely characterised 
signal transduction pathway in mammalian cells that directly involves Ras is the Raf- 
MAPK kinase pathway (Bernards, 1995; Marshall, 1995). Ras functions through its 
guanine nucleotide-binding activity and its intrinsic GTPase activity. Upon activation by 
guanine nucleotide exchange factors, such as GRB2-SOS complex, Ras will exchange 
GDP for GTP, stimulating Ras to undergo a structural conformational change upon GTP- 
binding and activating downstream effectors such as Raf-1 kinase, a serine/threonine 
switch which phosphorylates and activates its downstream target, MAPKK/ERK. These 
kinases will eventually activate gene expression in the nucleus to stimulate cellular
23
proliferation or differentiation events. GAPs act as upstream regulators of Ras by 
stimulating the intrinsic GTPase activity of Ras, which is otherwise a very slow process. 
Downstream effector functions for GAP have also been reported (Boguski and 
McCormick, 1993).
In addition, studies in Drosophila melanogaster and in mice have shown that 
neurofibromin modulates the activity of the rutabaga-encoded adenylyl cyclase (AC) 
(Guo et al., 2000; Tong et al., 2002), an enzyme crucial for cAMP signaling. 
Neurofibromin has also been shown to associate with microtubules (Xu and Gutmann,
1997), suggesting that it is involved in the regulation of multiple signalling pathways in 
the brain. All of these biochemical pathways have been implicated in synaptic plasticity 
and in learning and memory- Figure 3.
Studies in D. melanogaster (60% protein wide homology for neurofibromin) showed that 
homozygosity for mutation of NF1 causes associative learning deficits and that these 
deficits are dependent on AC. Furthermore, the cAMP pathway is crucial for memory 
formation in a variety of vertebrate and invertebrate species (Silva et al., 1998), and AC 
activity is also impaired in cells from (lethal) homozygous mutant NF1 mice.
The human and mouse forms of neurofibromin are highly homologous (98% sequence 
similarity) (Bernards et al., 1993), as are the promoter sequences of the gene, suggesting 
that both the biochemistry of the protein and the transcriptional regulation of the gene are 
conserved across species (Hajra et al., 1994). Investigation of all the symptoms of NF1 in 
a single mouse has proven difficult. However the effects of NF1 mutations in humans and 
mice show interesting parallels. For example, in mice and probably in humans,
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Figure 3 Neurofibromin accelerates inactivation of active GTP-bound Ras, such that NF1 loss in specific 
cells results in increased Ras activity and dysregulated cell growth. In addition, neurofibromin may also be 
required for cAMP- and protein kinase A (PKA)-mediated gene transcription.
the complete loss of neurofibromin is lethal (Brannan et al., 1994; Jacks et al., 1994). 
Aged mice heterozygous for a targeted disruption of the NF1 gene (Nfl+/') have an 
increased incidence of phaeochromocytomas, and myeloid leukaemias, two phenotypes 
observed in NF1 patients. Moreover, mice carrying Nfl+/‘ mutations in particular cell 
populations develop neurofibromas (Cichowski et a l, 1999; Zhu et a l, 2002) and mice 
that carry linked cooperative (cis) mutations in Nfl and p53 develop soft tissue sarcomas, 
namely malignant peripheral-nerve-sheath tumours (MPNSTs) (Cichowski et a l, 1999; 
Vogel et a l, 1999). Skin pigmentation problems have also been observed in mice and 
humans (Atit et a l, 1999). In addition, NF1 mutations result in abnormal brain function 
in both species. As described for NF1 patients (Nordlund et al, 1995), mice carrying NF1 
mutations can develop low levels of region-specific astrogliosis (Rizvi et a l, 1999; Zhu 
et a l, 2001) and have learning deficits (Costa et a l, 2001; Silva et a l, 1997). Whether 
altered Ras signalling accounts for the neurocognitive deficit in NF1 has recently been 
considered (Costa et a l, 2001). Two NF1 isoforms I and II, are abundantly expressed in 
the brain. Costa et al examined the hypothesis that type II neurofibromin (which includes 
exon 23a) is critical to learning ability. By selectively targeting exon 23a, they generated 
a mouse (Nfl23a'A) lacking only type II neurofibromin. The mice develop normally, are 
viable and are not susceptible to tumour formation. They have, however, learning 
impairments similar to those of NF1 patients and Nfl+/‘ mice (that is they fare poorly in 
tasks relying on hippocampal function). Type I and II neurofibromins are believed to 
differentially regulate Ras-dependent signalling. Other studies have indicated that a 
perturbation in the balance of active and inactive Ras - in either direction - can result in 
learning impairments (Brambilla et a l, 1997; Silva et al, 1997). Costa et al later show
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that the learning deficits of N fl+/‘ mice can be rescued by genetic and pharmacological 
manipulations that decrease Ras function (Costa et al., 2002).
1.2.2 Expression of Neurofibromin
Although the complex distribution pattern of neurofibromin is now known in detail, there 
is no absolute correlation of protein expression with disease. Thus, patient's 
neurofibromin is expressed both in tissues affected in NF1 and in apparently unaffected 
tissues (Upadhyaya, 1998). The complexity of neurofibromin suggests that NF1 
mutations may act in more than one cell type to produce the manifestations of disease. 
For example, the three major cellular components of neurofibromas (neurons, Schwann 
cells and fibroblasts) all express neurofibromin. It is likely that many of the 
manifestations are due to abnormal interactions between affected cell types as well as 
cell-autonomous defects (Sherman et al 1998).
The normal distribution of neurofibromin has been investigated in chicken, mouse, rat 
and some human tissues. In all these species, neurofibromin accounts for a very low 
proportion of cellular protein, even in tissues with the highest neurofibromin expression, 
such as the brain (Daston et al., 1992). Neurofibromin distribution is similar across 
species. It is expressed ubiquitously from the onset of organogenesis to mid-stage 
embryonic development.
Three main categories of tissues can be distinguished with respect to neurofibromin
levels during development and differentiation (Sherman et al 1998):
a) spinal motor neurons, ganglionic neurons, some brain neurons, adrenal medullary
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cells and oligodendrocytes all increase their expression of neurofibromin concurrent 
with terminal differentiation and relatively high expression persists in the adult.
b) Skeletal and cardiac muscle show strong expression during development and no 
detectable expression in adults.
c) Other tissues such as lung, liver and kidney clearly express neurofibromin in 
development with no obvious peak, and the level in the adult is low or absent.
In discussing neurofibromin distribution, most studies have not discriminated among 
possible neurofibromin variants generated by alternative splicing. Exons 23a, 48a and 9a 
of the NF1 transcript can be alternatively spliced (Danglot et al., 1995). There are tissue 
specific differences in the relative levels of NF1 mRNAs.
The difference in neurofibromin distribution inside cells is demonstrated by analysis of 
neurons and keratinocytes in tissue sections using antibody staining (Malhotra and 
Ratner, 1994). Keratinocytes show plasma membrane neurofibromin localisation whereas 
in cerebellar Purkinje neurons it is localised to smooth endoplasmic reticulum (Nordlund 
et al., 1993). This shows that there are cell type specific differences in the subcellular 
localisation of neurofibromin. How this is regulated and the functional significance of 
differences are unknown. It could, in principle, be determined by specific NF1 splice 
variants, or the ratios of the variants, but this remains to be demonstrated. Other 
mechanisms such as differential expression of neurofibromin-binding partners could also 
influence neurofibromin intracellular localisation.
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1.2.3 Loss of heterozygosity (LOH) for the NF1 gene
Tumorigenesis in NF1 is believed to follow the 'two-hit' hypothesis postulated for 
tumour-suppressor genes, with one allele constitutively inactivated and the other 
somatically mutated (Cavanee et al 1983). Somatic loss of heterozygosity (LOH) has 
been described for NF1-associated malignancies (Xu et al 1992) and in benign 
neurofibromas, but only a few of the latter yielded a positive result (Colman et al., 1995). 
However, using a systematic approach of searching for somatic inactivation of the Nfl 
gene in neurofibromas, it has been shown that small subtle mutations occur with similar 
frequency to that of LOH in benign neurofibromas and that somatic inactivation of the 
NF1 gene is a general event in these tumours (Side et al 1992). Explanations given for the 
failure to detect LOH in some studies includes the difficulty in analysing a large gene and 
the availability of informative probes. But it is also possible, as described below, that 
NF1 tumours may occasionally arise due to inappropriate expression of edited or 
alternatively spliced isoforms of NF1. Until recently it was unknown whether 
neurofibroma formation requires NF1 LOH in a single cell type or in some specific 
complement of all the cell types commonly present in these tumours. Through the use of 
a conditional (cre/lox) allele, it has been shown that loss of NF1 in the Schwann cell 
lineage is sufficient to generate tumours. In addition, complete NF1-mediated 
tumorigenicity requires both a loss of NF1 in cells destined to become neoplastic as well 
as heterozygosity in non-neoplastic cells (Zhu et al., 2002). Therefore there is a 
requirement for a permissive haploinsufficient environment to allow tumorigenesis. The 
notion that tumour formation is a coordinated process in which incipient tumour cells
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recruit collaborating cells from the environment has established a firm foothold (Hanahan 
and Weinberg, 2000). Among the requirements, it has been acknowledged that cell cycle 
suppressors must be shut down, growth factor requirements must be eluded, blood vessel 
formation must be induced, and apoptotic signals must be evaded. NF1+/' mast cells 
invade pre-neoplastic nerves and remain present throughout the development of the 
tumour. Previous studies have described the enhanced proliferative properties of 
heterozygous mast cells from NF1 patients and from NF1+/* mice (Ingram et al., 2000). 
Given the breadth of cytokine expression found in degranulating mast cells, it is tempting 
to speculate that these cells could play a central role in the initiation of neurofibroma 
formation.
1.2.4 RNA Processing and clinical variability in NF1
One of the intriguing features of NF1 is the great variation in expressivity of disease traits 
across those affected. To date, the underlying source of this variation remains somewhat 
unclear. An analysis of variation in expression of NF1 features in families including 
twins, concluded that this was determined to a large extent by the genotyping at other 
'modifying' loci and that these modifying genes were trait specific (Easton et al., 1993). 
However, evidence suggests that aberrations in normal NF1 RNA processing may be 
involved (Skuse et al 1997). This evidence includes: (i) differences in the relative ratios 
of the type I and type II splice variants in NF1 tumours compared with non-tumour 
tissues; (ii) unequal expression of mutant and normal NF1 alleles in cultured cells derived 
from NF1 patients; (iii) the existence of NF1 tumours which display NF1 mRNA editing
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levels that are greater than that seen in non-NFl tumours; and (iv) tissue-specific and 
developmental stage-specific expression of particular alternative NF1 transcripts (Skuse 
et al 1997).
1.2.4.1 Alternative transcript expression.
Expression of type I and type II transcripts appears to respond to extracellular factors, 
thereby suggesting that modulation of NF1 gene expression of these two alternative 
transcripts is regulated by some epigenetic mechanism. Changes in the levels of NF1 
gene expression have been observed in response to environmental factors such as cerebral 
ischaemia in the rat (Giordano et a l, 1996). A study of the rat phaeochromocytoma cell 
line PC 12 revealed that the relative levels of the type I transcript compared with type II 
changed in response to treatment with a variety of factors, including nerve growth factor 
(NGF) and dexamethasone among others (Metheny and Skuse, 1996). Other transcripts 
identified are: type III (rodent), which includes exon 23b, type IV (rodent), which 
includes exons 23b but not 23a. Transcripts have also been identified which differ outside 
of the GRD. One such transcript contains an additional exon (9br) between exons 9 and 
10a that is only expressed in the brain (Danglot et al, 1995). Another involves an 
alternative splicing event that occurs at the 3' end of the NF1 transcript to produce a 
transcript containing exon 48a which is observed in developing and adult skeletal and 
cardiac muscle (Gutmann and Collins, 1993). Transcripts containing exon 48a but not 
23a, are termed type 3 and those with both 48a and 23a are type 4. This observed tissue 
specificity is, at first glance, unexpected due to the lack of muscle pathology in NF1 
patients. However, findings of cardiac abnormalities in transgenic mice homozygously
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deficient for NF1 suggest that NF1 gene expression is necessary for proper muscle 
development (Brannan et al., 1994). Finally the N-isoform lacks the region encoding the 
GRD, and includes an additional four amino acids normally found in the carboxy 
terminus (Suzuki et al., 1992). Expression of this centrally truncated transcript has been 
observed in both normal and brain tumours and its function remains unclear.
1.2.4.2 Unequal allelic expression
RNA from cultured fibroblasts derived from 15 NF1 patients and from whole white blood 
cells from another patient was analysed for NF1 allele expression (Hoffmeyer et al, 
1995). The studies revealed variable levels of allelic expression. The investigators also 
looked at allelic expression of NF1 transcripts in nuclear RNA. The ratios were 
consistently similar. These results suggest that the detected unequal NF1 allelic 
expression arises either from different stability or differential transport to the cytoplasm.
1.2.4.3 NF1 mRNA editing
RNA editing is a form of post-transcriptional processing by which the coding sequence of 
the RNA is changed from that which is prescribed by the encoding DNA. RNA editing 
thus provides another level by which gene expression can be regulated and protein 
diversity expanded. Base modification mRNA editing involves the chemical modification 
of existing nucleotides within the transcript to convert them to different ones. This 
mechanism acts on the NF1 mRNA so that a cytidine at position 3916 is deaminated to
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become a uracil (Skuse et a l, 1996). The consequence of NF1 nRNA editing is that an in 
frame stop codon is introduced in the 5* portion of the NF1 GRD. This may result in an 
expression of a truncated form of neurofibromin, lacking the complete GRD, or may lead 
to an unstable mRNA through nonsense mediated decay. Which of these two alternatives 
applies to the edited NF1 mRNA remains to be determined. In either case there is 
potential to inactivate NF1 tumour suppressor activity without involving mutations to the 
NF1 gene itself. It is possible that a shortened form of neurofibromin is expressed which 
either has a unique function compared with the full-length protein or somehow interacts 
with the full length protein to regulate its function. Whether or not NF1 mRNA editing 
plays a role in the pathogenesis of NF1 or NF1 tumours has not been proven definitely. A 
study of 23 tumours resected from NF1 and non-NFl patients demonstrated a trend for 
higher levels of NF1 mRNA editing in tumours compared with non tumour tissues 
(Cappione et al, 1997). Interestingly, neither mouse nor rat mRNAs undergo RNA 
editing (Skuse et al 1996). This is most likely due to sequence divergence between the 
human and murine species at the editing site.
The findings described in the above three sections suggest that the classical 2-hit model 
for tumour suppressor inactivation used to explain NF1 tumorigenesis can be expanded to 
include the post-transcriptional mechanisms which regulate NF1 gene expression. 
Aberrations in these mechanisms may lead to the pathogenesis of NF1 and may play a 
role in the observed clinical variability.
33
1.3 Mutation analysis and genotype-phenotype correlations
Despite the good diagnostic criteria, many young children and some older patients fail to 
meet them and are in limbo regarding the future, needing regular follow-up to see 
whether further features appear that would confirm the diagnosis. For these patients, and 
for families who desire prenatal diagnosis, a conclusive test would be helpful.
Mutation detection in NF1 has been made difficult by a number of factors: the large size 
of the gene, the existence of a number of homologous pseudogene sequences spread 
throughout the genome, the lack of defined mutational hotspots, and many intronic 
changes that appear to affect splicing. To overcome these problems, a variety of 
techniques have been employed for screening the NF1 gene and a database of NF1 gene 
mutations, as reported to the International NF1 Genetic Analysis Consortium, is now 
available on the Internet (http://www.clam.com/nf/nflgene). Most studies have been 
based on single-strand conformation polymorphism (SSCP) (Ainsworth et al., 1993; 
Cawthon et al., 1990; Upadhyaya et a l, 1994; Upadhyaya et al., 1992), heteroduplex 
analysis (HDA) (Shen et al., 1993; Upadhyaya et al., 1994), temperature gradient gel 
electrophoresis (TGGE) (Boddrich et al., 1995), denaturing gradient gel electrophoresis 
(DGGE) (Valero et al., 1994), chemical cleavage of mismatch (Purandare et al., 1995), 
the protein truncation test (Heim et a l, 1995), and long reverse transcriptase-polymerase 
reaction(RT-PCR) (Martinez et al., 1996). The early studies were focussed on specific 
regions or groups of exons making it difficult to determine the respective mutation 
detection efficiencies of these methods in the context of NF1 and the distribution of these 
mutations within the gene. However no single technique has been 100% effective at
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identifying pathological lesions within the NF1 gene. More recently three studies have 
used combinations of techniques to examine the entire NF1 gene. In the largest study to 
date involving 500 patients, Fahsold (Fahsold et al., 2000) used a protein truncation test 
(PTT), TGGE, and direct genomic sequencing (DGS) to examine all individual exons, 
finding sequence variants in 301 patients. Within these variants 278 mutations were 
considered pathogenic. In the smaller studies the methodologies were used sequentially to 
raise mutation detection rates. In the study of Ars et al (Ars et al., 2000) on 80 patients, 
using cDNA-SSCP and HD A a detection rate of 70-80% of mutations was achieved. 
Messiaen et al (Messiaen et al., 2000) used PTT, FISH, southern blot and cytogenetic 
analysis in 67 patients and reported a detection rate of 95% including a high frequency of 
unusual splicing defects. The most sensitive single technique for mutation detection 
reported to date (73%) is the protein truncation test (Park and Pivnick, 1998) but this will 
not pick up any missense mutations.
Despite the high rates of mutation detection, little evidence for a genotype/phenotype 
correlation has emerged from this previous work in NF1. This is perhaps not surprising 
given the considerable intra-familial variability in NF1, which suggests that epigenetic 
and other factors determine the clinical phenotype. However, a relationship between 
whole gene deletions (thought to occur in 10% of cases) and a more severe NF1 
phenotype has been reported. The definition of severe in this context is unclear, but 
appears to include facial anomalies, learning disability or mental retardation and large 
numbers of cutaneous neurofibromas (Cnossen et al., 1997; Kayes et al., 1994; Wu et al, 
1995). Some ascertainment bias may play a role as the numbers in these studies are small
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and more severely affected individuals are more likely to be investigated for large-scale 
genomic alterations. Other genes are likely to play minor roles in the NF1 phenotype 
(Easton et al., 1993) and hints of phenotype/genotype correlations exist in a few scientific 
publications. For example, a family with only cafe-au-lait spots appears to show linkage 
to the NF1 gene region, despite having no other signs of NF1 (Abeliovich et a l , 1995). A 
small study suggested that large NF1 deletions are more common in patients who develop 
malignancies such as malignant peripheral nerve sheath tumours (Wu et al., 1999a). In 
another example, all five members of a family with an exon 46 frameshift mutation 
consistently showed spinal neurofibomas and cafe-au-lait spots, with other features only 
variably found. There are also a few reports about NF1 gene mutations in patients who fit 
other syndrome diagnoses better, which suggests that different clinical disorders might be 
allelic: two reports of families/patients with Watson syndrome (which has some 
overlapping features) having NF1 gene mutations (Tassabehji et al., 1993; Upadhyaya et 
al, 1992) and a patient with LEOPARD syndrome (Wu et al, 1996).
1.3.1 Noonan-Neurofibromatosis syndrome (NFNS)
An association with Noonan syndrome and NF1 was first reported in 1985 (Allanson et 
al, 1985). They presented a total of seven patients with NF1 and additional features of 
Noonan syndrome. Noonan syndrome (NS) is another dominantly inherited disorder with 
an estimated incidence of 1 in 1,000-2,500 live births. It is characterised by dysmorphic 
facial features, proportionate short stature and heart malformations (most commonly
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pulmonic stenosis and hypertrophic cardiomyopathy). Webbed neck, chest deformity, 
cryptorchidism, mental retardation and clotting abnormalities are also frequently 
associated with this disease (Mendez et al 1985). A gene causing this syndrome in 
approximately 50% of cases, a protein tyrosine phosphotase PTPN11, has recently been 
identified (Tartaglia et al., 2001). Subsequent to the first reports, approximately 30 
further cases of NF-Noonan syndrome have been reported. It has been suggested that this 
phenotype of Neurofibromatosis-Noonan syndrome (NFNS) is more common than 
previously appreciated, as Colley et al (Colley et al., 1996) examined 94 sequentially 
identified patients with NF1 from their genetic register and found Noonan features in 12. 
There are four possible mechanisms for this association of Noonan syndrome with NF1: 
(a) a chance occurrence of NS and NF1, (b) NFNS as an unusual variant of NF1 (with 
mutations in the NF1 neurofibromin gene), (c) NFNS as an unusual variant of NS, and (d) 
NFNS as a distinct genetic disease. While the original cases in the literature were isolated 
and reported as a new syndrome entity in which vertical transmission has been reported 
(Quattrin et al., 1987), the genetic register study suggest an association. Large studies of 
NS (Sharland et a l, 1992) make no reference to patients with CAL spots or 
neurofibromas suggesting that NF1 features do not occur frequently in classical NS and 
that NFNS is unlikely to be an unusual variant of NS. However, smaller studies have 
described CAL macules (Ahlbom et al., 1995). There has been one family reported with 
evidence for the NF-NS phenotype being additive (Bahuau et a l, 1998). In this family, 
the two autosomal dominant disorders were inherited together by some members of the 
family. And a further 3 cases were reported by Colley et al (Colley et al 1996).
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2. RNA SPLICING
2.0.1 Mutations affecting splicing
Splicing signals are a frequent target of mutations in genetic diseases and cancer. In a 
widely cited survey, Krawczak et al (Krawczak et al, 1992) estimated that at least 15% 
of point mutations that result in a human genetic disease cause RNA splicing defects, a 
figure that is supported by the annotation of ~16,000 point mutations in the current 
Human Gene Mutation Database. Most splicing mutations that are considered in these 
surveys directly affect the standard consensus splicing signals, and typically lead to 
skipping of the neighbouring exon. Less frequently, the mutations create an ectopic splice 
site or activate a cryptic splice site, thereby changing the overall splicing pattern of the 
mutant transcript.
Mutation analysis of a gene will generate sequence variations that can generally be 
classified into the following groups: nonsense, frameshift, missense, splice site or silent 
mutations. However these classifications might be misleading when not supported by 
characterisation at the mRNA level, because mutations that affect sequences that are 
important for splicing modulation are likely to have a profound effect on the translated 
product. For example, if a missense causes exon skipping, the mutant protein, instead of 
having just a single amino-acid difference from the wild-type, will carry a large internal 
deletion or, if the open reading frame (ORF) is not maintained, an entirely different and 
probably shorter carboxy-terminal domain.
Indeed, there is growing evidence that misclassification of mutations might commonly 
occur, and that the general extent of splicing mutations has been underestimated. In a
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recent study (Ars et al., 2000) of NF1 where analysis was at the DNA and RNA level 
~50% of the patients (26 out of 52) were found to have disease due to mutations that 
result in aberrant splicing. Of these mutations 13% (7 out of 52) would have been 
erroneously classified as ffameshift, missense or nonsense mutations if the analysis had 
been limited to genomic sequence. Table 2 (Cartegni et al., 2002) lists missense and 
silent mutations associated with altered splicing in the literature. The fact that even 
mutations that are predicted to be translationally silent cause exon skipping is particularly 
significant, because these mutations must act at the RNA level (except for possible subtle 
effects on translation efficiency owing to codon preferences). These mutations probably 
alter cis -elements that are important for correct splicing. Furthermore, it is very likely 
that such mutations are generally under-reported, because they might be incorrectly 
assumed to be neutral polymorphisms that do not merit further characterisation. For 
nonsense mutation-altered splicing (NAS) four possible mechanisms have been proposed 
(Cartegni et a l, 2002): a) In the nuclear scanning model a presumptive translation-like 
machinery in the nucleus scans the reading frame and surveys its integrity before 
splicing, b) Indirect nonsense mediated decay (NMD) model, c) Secondary-structure 
disruption, d) Exonic splice enhancer (ESE) disruption. In the latter theory, the premature 
stop codon generated by the mutation, fortuitously disrupts the recognition motif for an 
RNA-binding protein that enhances splicing, such as an SR protein, and exon inclusion is 
no longer favoured.
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Gene Mutation Exon Gene Mutation Exor
Missense Silent
Mutations Mutations
ADA A215T 7 APC R623R 14
ATM E2032K 44 AR S888S 8
ATP7A G1302R 4 ATM S706S 16
BRCA1 E1694K 18 S1135S 26
CFTR G58E 9 CYP27A1 G112G 2
D565G 12 FAH N232N
F8 R1997W 19 FBN1 121181 51
FAH Q279R 9 HEXA L187L 5
FBN2 D1114H 25 HMBS R28R 3
FECH A155P 4 HPRT1 F199F 8
HEXB P404L 11 ITGB3 T420T 9
HMBS E29L 3 LIPA Q277Q
HPRT1 G40V 2 MAPT L284L* 10
R48H 3 N296N* 10
A161E 6 S305S* 10
G180E 8 MLH1 S577S 16
G180V 8 NF1 K354K 8
E182K 8 PAH V399V 11
P184L 8 PDHA1 G185G 6
D194Y 8 PKLR A423A 9
E197K 8 PTPRC P48P 4
E197V 8 PTS E81E 4
D201V 8 RET I647I 11
1L2RG R285Q 6 SMN1 F280F 7
IVD R21C 2 TNFRSF5 T136T 5
R21P 2 UROD E314E 9
D20N 2
MAPT N279K*
S305N*
10
MLH1 R659P 17
Table 2 Missense and silent mutations associated with altered splicing. * mutations that increase 
exon inclusion. ADA, adenosine deaminase; APC, adenomatosis polyposis coli; AR, androgen 
receptor; ATM, ataxia telangectasia mutated; ATP7A, ATPase, Cu transporting, a-polypeptide; 
BRCA1, breast cancer 1; CFTR, cystic fibrosis transmembrane conductance regulator; CYP27A1, 
sterol-27-hydroxylase; F8, coagulation factor VIII, procoagulant component; FAH, 
fumarylacetoacetate hydrolase; FBNl, fibrillin 1; FBN2, fibrillin 2; FECH, ferrochelatase; HEXA, 
hexosaminidase, a-polypeptide; HEXB, hexosaminidase, (3-poly peptide; HMBS,
hydroxymethylbilane synthase; HPRT1, hypoxanthine phosphoribosyltransferasel; IL2RG, 
interleukin2 receptor-y; ITGB3, integrin-p3; IVD, isovaleryl coenzyme A dehydrogenase; LIPA, 
lipase A; MAPT, microtubule-associated protein tau; MLH1, mutL homologue; PAH, phenylalanine 
hydroxylase; PDHA1, pyruvate dehydrogenase; PKLR, pyruvate kinase, liver and red blood cells; 
PMM2, phosphomannonutase2; PTPRC, protein-tyrosine phosphatase receptor type C; PTS, 6- 
pyruvoyltetrahydropterin synthase; RET, rearranged during transfection protooncogene; RHAG, 
Rhesus blood group-associated glycoprotein; SMI, survival of motor neuron 1; TNFRSF5, tumour- 
necrosis factor receptor superfamily, member 5 (CD40); UROD, uroporphyrinogen decarboxylase.
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2.0.2 Fundamentals of RNA splicing
The coding sequences of most eukaryotic genes are interrupted by non-coding stretches 
of DNA known as intervening sequences or introns. The presence of intervening 
sequences was first described in non-coding region of adenovirus (Berget et al., 1977; 
Chow et al., 1977), but was quickly shown to be a common feature of cellular genes. In 
fact in 1977, for the first time, Jeffreys and Flevell described the presence of “large 
insert” in the coding sequence of rabbit a-globin gene (Jeffreys and Flavell, 1977). Exons 
must be excised from primary transcripts and the flanking exon joined together before the 
mature RNA is exported from the nucleus. This process is called splicing and occurs in a 
macromolecular complex known as a spliceosome, which consists of five small 
ribonuclear particles (snRNPs) and a large number of non-snRNP protein splicing factors. 
The primary transcript of protein coding genes - pre-mRNA, or heterologous nuclear 
RNA (hnRNA), is synthesised by RNA polymerase II within the nuclei of eukaryotic 
cells. Its average size is much larger than mRNA and because of this it is very unstable. 
From the time hnRNA emerges from the transcription complex, and throughout the time 
it is in the nucleus, it is associated with proteins. The physical form of hnRNA is a 
ribonucleoprotein particle (hnRNP) in which hnRNP proteins (which comprise at least 20 
distinct proteins) bind cooperatively to nascent pre-mRNA to form complexes 
encompassing about 500 nucleotides of RNA (Dreyfuss et al., 1993).
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2.1 The spliceosome
The removal of introns from pre-mRNA is a critical aspect of gene expression. The 
inaccurate recognition of exon-intron boundaries or the failure to remove an intron 
generates aberrant mRNAs that are either unstable or code for defective or deleterious 
protein isoforms. This reaction takes place in the spliceosome, which is formed by several 
RNP subunits termed uridine-rich small ribonucleoproteins (UsnRNP), and numerous 
non-snRNP splicing factors. Each UsnRNP consists of a UsnRNA complexed with a set 
of eight Sm or Sm-like proteins and several particle-specific proteins (Will, 1997).
The spliceosome acts through a multitude of RNA-RNA, RNA-protein and protein- 
protein interactions to precisely excise each intron and join exons in the correct order 
(Madhani and Guthrie, 1994; Nilsen, 1994).
2.1.1 The Splicing Reaction
Splicing takes place in two catalytic steps involving two consecutive trans-esterification 
reactions (Lamond, 1993). During step I, an adenosine residue generally located within 
100 nucleotides of the 3’ end of the intron, in a sequence element known as the branch 
point sequence (BPS), carries out a nucleophilic attack on the 5’ splice site. This reaction 
generates the splicing intermediates (free exon 1 and lariat-exon 2). During step II, exon 
1 attacks at the 3 * splice site to generate splicing products (spliced exon and lariat intron)- 
Figure 4.
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ynytrA c-pCUR — if- yAGpexon 1 exon 2
5' splice site branchpoint 3' splice site
ynytrA c yAGp exon 2
exon 1 p exon 2
ynytrA c yAGp
Figure 4 Exon splicing and lariat formation
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2.1.2 Sequence elements (cis) on pre-mRNA required for splicing
The exact sites for the trans-esterification reactions are defined by consensus sequence, 
primarily within the intron, around the 5’ and 3’ splice site (Shapiro and Senapathy, 
1987). These sequences are highly conserved in yeast, despite the fact that only a 
minority of genes in S. cerevisae has introns, but much less so in mammals.
The first consensus sequence is called 5’ splice site and is relatively short. In mammals it 
is AG/GURAGU (where R=purine) and the first two bases of the intron are an essential 
requirement for the splicing reaction, although they are not the only important bases 
(Aebi et al., 1987). The second consensus at 3’ splice site is defined by three separate 
elements: the branch site, the polypyrimidine tract and the 3’ splice site (Reed, 1989). 
Together these elements make up a loosely defined 3’ splice site region, which may 
extend up to 100 nucleotides into the intron, close to the 3’ splice site. The branch site 
consensus is YNYURAC (Y=pyrimidine) where the underlined “A” residue is that at 
which branch point formation occurs (Nelson and Green, 1989). However in higher 
eukaryotes there is considerable flexibility, in these sequence requirements. The branch 
point is located 18-40 nucleotides upstream of the point of cleavage of the RNA. A 
polypyrimidine tract is usually found between the branch site and 3’ splice site. This 
sequence is more pronounced in mammals than in yeast, where the length of this tract is 
variable and for this reason introns are classified as short and long polypyrimidine-tract 
introns, which have distinguishable properties in splicing. The 3 ’ splice site junction is 
defined by YAG/G.
As previously mentioned, consensus sequences in higher eukaryotes are less conserved
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than in yeast. However, there are many sequences in mammalian transcripts that match 
the consensus splice sites but most of them are pseudo-splice sites. To increase the 
overall fidelity of the splicing reaction additional sequences are present in exons and in 
introns, these are called enhancers or silencers. Their features and role during the splicing 
will be described in section 2.4.
2.2 Protein components involved in splicing
In higher eukaryotes, over 70 spliceosomal proteins have been identified thus far. 
Although their precise role in some cases remain unknown, spliceosomal proteins have 
been implicated in a growing number of functions. Most of these proteins share very 
similar structural features such as RNA binding domains and/or protein binding domains.
2.2.1 Small Nuclear Ribonucleoprotein Particles (snRNPs)
snRNP particles form part of the catalytic macromolecular complex of the spliceosome. 
Each snRNP particle consists of an snRNA molecule complexed with a set of eight Sm or 
Sm-like proteins and several particle specific proteins (Will and Luhrmann, 1997). The 
major spliceosomal snRNPs Ul, U2, U4, U5 and U6 are responsible for splicing the vast 
majority of pre-mRNA introns (U2-type introns). A group of less abundant snRNPs, Ul 1, 
U12, U4atac and U6atac, together with U5, are subunits of the so-called minor 
spliceosome that splices a rare class of pre-mRNA introns, denoted U 12-type (Burge,
1999).
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snRNAs U l, U2, U4, U5 and U6 are characterised by their small size, metabolic stability 
and a high degree of sequence conservation (Kambach et al., 1999). They show high 
complementarity to the consensus splice sites on the pre-mRNA.
The snRNAs are transcribed by RNA polymerase II, with the only exception of U6 (and 
presumably U6atac snRNA) that is transcribed by RNA polymerase III and entirely 
assembled in the nucleus. The other pre-snRNAs must be transported to the cytoplasm 
where snRNPs assembly with Sm proteins is initiated and then re-imported into the 
nucleus thanks to the bipartite snRNP nuclear localization signal (NLS) formed by 
Py3cap and the Sm core domain (Fischer et al., 1993). The U4 and U6 snRNAs are 
extensively base paired (amounting to >20 base pairs) in the U4/U6 snRNP. They 
associate in the nucleus forming a larger ribonucleoprotein complex. The U5 snRNA then 
assembles in an ATP dependent reaction with the U4/U6 snRNP giving the U4/U6-U5 
three snRNPs particles (Konarska and Sharp, 1987).
The structural core of snRNPs is formed by eight proteins, called Sm proteins, B’, B, Dl, 
D2, D3, E, F and G. This class of common proteins play an essential role in the 
biogenesis of the snRNPs. The Sm proteins form three distinct heteromeric complexes 
prior to their interaction with the highly conserved Sm site (PuAU4-6GPu flanked by two 
stem-loop structures) of the Ul, U2, U4 and U5 snRNAs (Raker et al., 1996). Sm-like 
proteins belonging to the Sm protein family are specifically required for the assembly of 
U6 snRNA. This subclass of Sm-like proteins shares the conserved structural motif 
characteristic of all Sm-proteins family members (Mayes et al., 1999), but can be isolated 
as a heteromeric complex in the absence of U6 snRNA (Achsel et al., 1999).
Besides Sm proteins there are other particle-specific proteins that associate with snRNAs
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(Will, 1997). U1-70K and Ul-A proteins bind directly to the RNA and are involved in the 
splice site recognition and selection, while Ul-C associates via protein-protein 
interactions with U1-70K and other Sm proteins. A subset of U2 snRNP proteins also 
play a critical role in tethering the U2 snRNP to the pre-mRNA. These proteins include 
the heteromeric splicing factors SF3a and SF3b (Brosi et al.t 1993) and bind 20- 
nucleotide region just upstream of the branch site in a sequence-independent manner 
(Champion-Amaud and Reed, 1994; Gozani et al., 1996). At least five different proteins 
associate with U4/U6 snRNP, including a 15.5 KDa protein, polypeptides of 20, 60 and 
90 KDa that form complex with one another (Teigelkamp et al., 1998). U5 snRNP 
particle presents a complex protein composition. U5 220KDa protein cross-links to both 
5’ and 3’ splice sites, as well as to the exon flanking these two splice sites (Umen and 
Guthrie, 1995).
2.2.2 Non-snRNP splicing factors 
• U2AF
U2 snRNP auxiliary factor (U2AF) is an essential splicing factor that is required for the 
binding of U2 snRNP to the pre-mRNA (Ruskin et al., 1985). This factor is a heterodimer 
composed of two subunits named U2AF65 and U2AF35. U2AF65 contains two 
functional domains consisting of a sequence specific RNA binding-region composed of 
three canonical RNA-recognition motif (RRM) and a N-terminal short serine/arginine 
domain involved in protein-protein interaction (Zamore and Green, 1991). U2AF65 
interacts with the polypyrimidine tract. It participates in the recognition of the essential
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AG dinucleotide at 3’ splice site at the earliest stage of spliceosome assembly (Wu et al., 
1999b). These studies have also shown that U2AF35 is essential for splicing ‘AG- 
dependent’ introns, which are introns with a weak polypyrimidine tract, but is 
dispensable for ‘AG-independent’ introns, which have a strong 3’ splice site.
• SR proteins
SR proteins are a superfamily of highly conserved proteins that play an important role in 
splicing control (Fu, 1993; Zahler et al., 1992). The name SR proteins reflect the 
presence of a characteristic serine/arginine domain present in the carboxy-terminal region 
of these proteins. Sequence analysis of SR proteins revealed the presence of at least one* 
amino-terminal RNA recognition motif (RRM) required for the interaction with pre- 
mRNA. Various human SR proteins have been identified using different techniques. 
Currently the SR protein family contains 10 known members: SRp20, SRp30 (SF2/ASF), 
SRp30b (SC35/PR264), SRp30c, SRp40, SRp46, SRp54, SRp55, SRp75 (Graveley,
2000). SR proteins are functionally redundant in the splicing of some introns, but exhibit 
unique functions in the removal of others (Kawano et al., 2000; Longman et al., 2000). 
They participate in both constitutive and alternative splicing (discussed in section 2.4). It 
has been demonstrated that the initial binding of SR proteins with pre-mRNA is sufficient 
to commit the splicing pathway and to facilitate spliceosomal assembly (Fu, 1993). The 
RRMs mediate RNA binding and determine substrate specificity for individual SR 
proteins. The hallmark of the RS domain is its significant post-translational 
phosphorylation of serine residues (Gui et al, 1994; Roth et al., 1991). The 
phosphorylation step is required for the dissociation of the splicing factors from nuclear
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speckles, the nuclear compartments enriched in proteins involved in pre-mRNA splicing, 
and the consequent recruitment to the sites of transcription (Misteli et al., 1998).
2 3  The Spliceosomal Complex
Two of the main functions of the spliceosomal snRNPs are to recognise the 5’ and 3’ 
intron/exon boundaries and to assemble onto these sites the macromolecular enzyme that 
catalyse the splicing reaction. In mammals four distinct spliceosomal complexes, which 
form in the temporal order E, A, B and C, have been detected (Figure 5). These general 
steps in spliceosomal assembly are now well understood, and its consequent recruitment 
to sites of transcription (Misteli et a l, 1998).
2.3.1 General model for spliceosome assembly and spliceosome cycle
Assembly of the major spliceosome is initiated by the ATP-dependent recognition of the 
5’ splice site by the U1 snRNP, which leads to the formation of the spliceosomal complex 
E. This interaction is mediated by base pairing of the U1 snRNA with the 5’ splice site, as 
well as by protein-protein and protein-pre-mRNA interaction involving U1-70K and Ul- 
C proteins (Will and Luhrmann, 1997). Novel insights into spliceosomal assembly come 
from studies in S. cerevisae which have shown that the first proteins that interact with the 
5’ splice site during the commitment complex (E complex counterpart) formation are the
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Figure 5. Spliceosome assembly pathway
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cap-binding complex protein CBC80 and seven U1 snRNP (Zhang and Rosbash, 1999). 
Another important event that occurs during formation of the E complex is the recognition 
of the 3’ end of the intron. U2 snRNP association occurs in the absence of ATP and does 
not require branch point sequence interaction. It first binds loosely to the pre-mRNA in 
the E complex via U2-snRNP associated protein SF3b and the U2AE heterodimer.
Then an ATP-dependent process leads to stable binding of U2-snRNP to the branch point 
sequence in the A complex and this is facilitated by the presence of other proteins such as 
SF3A and SF1 (Will and Luhrmann, 1997). The next major event after A complex 
assembly is the binding of U4/U5*U6 tri-snRNPs at the 5’ splice site to form the B 
complex. At this time many structural snRNPs rearrangements occur leading to the 
formation of a complex RNA-RNA network within the spliceosome. The U4AJ6 base 
pairing interaction is disrupted and U6 snRNA base pairs with U2 snRNA and also the 5’ 
splice site. Furthermore, U5 snRNA loop I base pairs with exon sequence at the 5’ splice 
site and later with exon sequences at 3’ splice site. The 5’ and 3’ splice sites are also 
contacted by the U5-220 KDa protein (Umen and Guthrie, 1995), which has been 
reported to affect the tertiary interaction between the splice sites and U6 snRNA (Collins 
and Guthrie, 1999).
An unsolved problem is the catalysis of RNA in pre-mRNA splicing. It is widely believed 
that this is mediated by RNA. The spliceosome is a metallo-enzyme (Sontheimer et al., 
1997; Steitz and Steitz, 1993) and from recent studies has been shown that U6 snRNA 
coordinates metal ion thus contributing to pre-mRNA splicing (Yean et al., 2000). U6 is a 
good candidate for catalysis because it is highly conserved through evolution and also 
forms intramolecular and intermolecular helices that are analogous to autocatalytic group
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II introns.
2.3.2 Early Complex Formation: Intron and Exon Definition Model
Interactions between 5’ and 3’ splice sites and the factors that recognise them have been 
observed in the earliest steps of spliceosomal assembly. Two models of interaction have 
been proposed according to intron size- Figure 6.
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Intron definition model
Figure 6 Intron and
U1 snRNP
Exon definition model
exon definition models
a) Intron Definition Model
The first model suggested that the intron is the unit recognised by the splicing machinery. 
According to this model, a mechanism was proposed that recognised one splice site, then, 
following scanning through the intron located the second site (Lang and Spritz, 1983). 
Such interactions have been observed in in vitro mRNA splicing with short introns.
• The yeast model.
In yeast, messengers often have unique introns and their length is usually below 100 
nucleotides. This provides direct support for the pairing of splice sites model across 
introns during the first step of spliceosome assembly (Goguel and Rosbash, 1993).
• Vertebrate intron/exon architecture.
In vertebrates most exons are small and are flanked by long introns. However, some 
exceptionally long exons exist and when an expanded exon is placed in a gene in which 
the flanking introns are small, the exon is constitutively included.
• Drosophila intron/exon architecture.
In Drosophila most exons are 100 to 180 nucleotides in length; however 15% are more 
than 550 nucleotides. There are a number of genes in Drosophila that have an inverted 
intron/exon architecture with respect to the one found in vertebrate genes. In at least three 
Drosophila genes, 5’ splice site mutations of small introns cause intron retention instead 
of exon skipping as observed in vertebrates (Berget et al, 1977; Talerico and Berget, 
1994). As for vertebrate short exons, Drosophila short introns seem to have size 
limitations. Expanding the size of the short introns causes repression of splicing or 
activation of cryptic site. Further evidence for a particular mechanism in the recognition 
of short introns derives from the observation that spliceosomal complex A formation
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requires sequences at both ends of the intron but not a polypyrimidine tract, while in 
vertebrates it requires only sequence at the 3’ splice site including the polypyrimidine 
tract.
h) Exon Definition Model
In 1990 Susan Berget’s group proposed a model in which the exon was the unit 
recognised by the splicing machinery and the identification of splice sites was facilitated 
by interactions across the exon (Robberson et al., 1990). Basically the exon definition 
theory proposes that in pre-mRNAs with multiple short exons and long introns the 
splicing machinery searches for two closely spaced splice sites. This model explains 
splice site selection of most mammalian pre-mRNAs which contain very long introns and 
weakly conserved splice sites (Hawkins, 1988). According to this model, an interaction is 
first established between the 5’ and 3’ splice sites across the short exon, followed by an 
interaction across the long intron and the juxtaposition of the neighboring exons.
• Exon size requirement.
The exon length can affect splicing. Internal vertebrate exons have minimum and 
maximum length requirements (Hawkins, 1988).
Simultaneous recognition of splice sites bordering an exon suggests that a minimal 
separation between the sites might be required to prevent steric hindrance between the 
factors that recognise individual sites. This is demonstrated, when a constitutively 
recognised internal exon was internally deleted below 50 nucleotides and was skipped by 
in vivo splicing machinery (Dominski and Kole, 1991). In addition, Black et al (Black, 
1991) have shown that when the length of the N1 (neuron specific) exon is extended to
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109 nucleotides, the exon is constitutively included, implying that the exon is normally 
skipped because it is too short to allow spliceosomes to assemble at both ends 
simultaneously. Instead, the expansion in vitro of internal exons to lengths above 300 
nucleotides determines the activation of cryptic splice site inside the exon or exon 
skipping (Berget et al, 1977) demonstrating the exon length limitation for efficient 
splicing. In fact, less than 1% of known internal exons in vertebrates are longer than 400 
nucleotides.
On the other hand, expansion of internal exons in vertebrate genes with moderate to large 
introns have two phenotypes: activation of internal cryptic sites within the expanded 
exons to create small exons or skipping of the entire exon (Robberson et al., 1990).
• Effect of splice site mutations.
In vitro (Dominski and Kole, 1991; Talerico and Berget, 1994) and in vivo (Dominski 
and Kole, 1994; Xu et al., 1993) experiments revealed that mutations within splice sites 
influence the splicing of both introns flanking the exon and not only of the intron bearing 
the mutated splice site, as predicted from intron recognition oriented theories. 
Furthermore, mutations at the 5’ splice site are suppressed by mutations that improve the 
consensus of the upstream 3’ splice site (Carothers et al., 1993).
• A network of interactions span the exon.
Experiments carried out on the preprotachykinin pre-mRNA showed evidence for exon 
bridging interactions that occur between U1 snRNP bound at the 5’ splice site and 
U2AF65 bound at the 3’ splice site. U2AF65 is indeed recruited to the polypyrimidine 
tract by interactions with the downstream 5’ splice site and the U1 snRNP (Hoffman and 
Grabowski, 1992). SR proteins have been implicated in these interactions in different
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experimental models (see section 2.4.2.).
• Exon enhancer sequences.Altematively spliced exons with suboptimal splice sites can 
contain particular sequences that work as enhancers of splicing, helping in the 
recruitment of splicing factors to an exon otherwise not recognised. These sequences will 
be explained in section 2.4.
• First and last exon recognition.
The lack of one functional splice site at the first and the last exon indicate special 
mechanisms for their recognition. To have efficient removal of the first intron, the 
capping and the proteins that bind the cap are essential (Izaurralde et a l, 1994). Therefore 
both factors that recognise the cap and the 5’ splice site, are necessary to define the first 
exon. The last exon is usually longer than internal exons (average length 600 nucleotides 
versus 137). Removal of the last intron involves RNA splicing and polyadenylation 
factors (Gunderson and Kopito, 1994).
2.3.3 Splice site recognition and bridging interactions
One of the critical steps of the splicing reaction is initial recognition of the splice site that 
leads to formation of complex E. It has been proposed that splice site recognition and 
pairing across introns is promoted by a network of interactions involving the SR proteins. 
SF2/ASF and SC35 associate via their RS domain with another RS-domain containing 
protein the U1 snRNP component U1-70K at 5’ splice site (Eperon et al., 1993; Kohtz et 
al., 1994; Zuo and Manley, 1994).
SR proteins are also involved in the subsequent bridging interaction. Different models
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have been proposed for bridging interaction according to exon and intron size. In the 
intron bridging model U2ASF and SF1 cooperatively interact to recognize the branch 
point and the polypyrimidine tract (Berglund et al, 1997). The RS domain of U2AF35 
contacts SC35 that simultaneously interacts with the RS domain of U1 snRNP 70K 
protein and U1 snRNP is base paired to the 5’ splice site (Wu and Maniatis, 1993). These 
U2AF65-U2AF35-SR-U1 70K interactions were also proposed to function as cross-exon 
contacts in constitutive and regulated mammalian splicing (Reed, 1996; Zuo and 
Maniatis, 1996).
In Exonic Splicing Enhancer (ESE)-dependent splicing a different class of proteins are 
involved. These are SRml60/300 proteins (SR-related Matrix protein) that are SR repeats 
containing proteins that lack the RNA recognition motif. In this case a splicing co­
activator model for the function of SRml60/300 has been proposed. SRml60/300 
promotes splice-site pairing and splicing through multiple cooperative interactions with 
factors bound to pre-mRNA, including SR proteins, U1 and U2 snRNPs (Blencowe et al., 
1998; Eldridge etal., 1999).
2.4 Alternative splicing
Alternative RNA splicing is the process that allows the selection of different combination 
of splice sites within precursor mRNA- Figure 7. This process is seen in nearly all 
metazoan organisms as a means for producing functionally diverse polypeptides from a 
single gene (Lopez, 1998).
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Figure 7 Types of alternative splicing events.
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Alternative splicing is especially common in vertebrates. Alignment of EST sequences 
and mapping the resulting mRNA families to the human genome provided a minimum 
estimate that 35% of human genes show variably spliced products (Croft et a l , 2000). 
However, since ESTs derive from a limited number of tissues or developmental stages, 
and cover a small portion of each mRNA, the true percentage is likely much higher and is 
responsible for much of the complexity of the proteome. This partly explains the 
unexpected finding that the human genome might consist of only 31,000-39,000 genes 
(McPherson et al, 2001; Venter et a l, 2001). Because a single primary transcript can 
have several regions that each undergo alternative splicing, the resulting combinatorial 
effects of selecting different splice sites can be very pronounced, and genes that code for 
tens to hundreds of different isoforms are common (Graveley, 2001). There are also 
remarkable examples of hundreds and even thousands of functionally divergent mRNAs 
and protein being produced from a single gene. A recent discovery in Drosophila is a 
fascinating example of the extremely high number of proteins that can be produced from 
one gene. The DSCAM gene presents different exons used in a mutually exclusive 
manner. For each of these exons there are different numbers of alternative forms. If all 
the combinations of these exons were used, the single DSCAM gene would produce 
38,016 different DSCAM proteins (Schmucker et al, 2000).
Variation in mRNA structures takes many different forms (Lopez, 1998). Exons can be 
spliced into the mRNA or skipped. Introns that are normally excised can be retained in 
the mRNA. The position of either 5’ or 3’ splice sites can shift to make exons longer or 
shorter. In addition to these changes in splicing, alterations in transcriptional start site or 
polyadenylation site also allow production of multiple mRNAs. All of these changes in
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mRNA structure can be regulated in diverse ways, depending on sexual genotype, 
cellular differentiation, or the activation of particular cell signaling pathways.
The mechanisms that determine which splice sites are utilized and how this selection is 
regulated in different cell types or developmental stages have still not been precisely 
defined. However, much progress has been made in the identifying the cis-acting 
elements and the frans-acting factors involved in alternative splicing.
2.4.1 Involvement of Cis-Acting Elements in Splice Site Selection
The question of splice-site choice is intimately connected to the problem of normal 
recognition of constitutive splice sites. A feature shared by both regulatory sequences and 
splice-site signals is that they are usually short and often degenerate. Cw-acting 
determinants that influence competing splicing pathways include relative strength of 5’ 
splice site, the branch point sequence, the polypyrimidine tract, the proximity between 5 ’ 
splice site and branch point, sequences between the branch point-polypyrimidine tract 
and 3’ splice site. In some cases, the formation of pre-mRNA secondary structure 
participates in the regulation of splice site selection by modifying the physical distance 
within introns, or by being involved in the definition of the exon. Moreover, additional 
exonic or intronic sequences are often involved in the correct recognition of splice sites, 
when suboptimal splice sites are present. These sequences can act by increasing the 
recognition or decreasing it and are respectively named enhancers or silencers.
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• Exon/intron architectural requirements
As described in the previous section, the average vertebrate genes consists of multiple 
small exons separated by introns that are considerably larger. The average size of exons is 
137 nucleotides and exons longer than 300 nucleotides or shorter than 50 nucleotides are 
not favoured by splicing machinery.
A compensatory relationship between exon and intron size has been proposed. Sterner et 
al observed that large internal exons are problematic for recognition if they are flanked 
by large introns, suggesting that naturally occurring large vertebrates exons might be 
flanked by small introns (Sterner et al., 1996).
• The 5’ and 3’ splice site requirements
The strength of splice sites is a determinant in their selection. As previously described, at 
3’ splice site exon/intron junction the consensus sequence is determined by 4 bases, while 
at the 5’ exon/intron junction this consensus sequence is extended to 9 bases (Shapiro and 
Senapathy, 1987). The GU and AG dinucleotides at 5’ and 3’ intron boundaries are 
nearly invariant in higher eukaryotes and mutations in one of these conserved bases 
completely abolishes splicing (Langford et al., 1984). It has been reported in different 
studies that mutations of a weak splice site that take it closer to the consensus sequence 
can lead to constitutive recognition (Huh and Hynes, 1993; Muro et al., 1999).
Mutations affecting splice sites causing aberrant splicing are observed more frequently in 
the 5’ splice site region than in 3’ splice site region (Nakai and Sakamoto, 1994). 
Furthermore, altemative-exon splice sites deviate more from the consensus: their 5’ 
splice sites deviate from consensus sequence mostly at the +4 and +5 position, while
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adenosine is more frequently used at the -3 position of the 3’ splice site (Stamm et al., 
2000).
• The polypyrimidine tract
Recognition of branch point sequences in the metazoan can be affected by the adjacent 
polypyrimidine tract (Mullen et al., 1991; Reed, 1989). It has been shown that 
progressive deletion of the polypyrimidine tract abolishes lariat formation, spliceosome 
assembly and splicing (Mullen et al, 1991; Roscigno et al, 1993).
Despite the important role of polypyrimidine tract in splicing, there appears to be great 
flexibility in the specific sequence of a given tract, for example the number of uridines 
involved (Norton, 1994; Roscigno et a l, 1993).
The length of the polypyrimidine tract is also important. In fact, as the number of 
consecutive uridines decreases, the location of pyrimidine tract becomes increasingly 
important showing a position dependent effect. Short tracts immediately adjacent to the 
3’ splice site are utilised more than twice as much as short tracts adjacent to the branch 
point (Coolidge et a l, 1997).
• The branch point sequence requirement
While in yeast there is an invariant branch point sequence (UACUAAC) which base pairs 
with U2 snRNA, in metazoan this sequence is not highly conserved. However, several 
lines of evidence suggest that the mammalian branch point is specified primarily by its 
proximity to the 3’ splice site. Most branch points have been mapped within 18-40 
nucleotides of the 3’ splice site (Reed and Maniatis, 1985; Ruskin et a l, 1985). There are
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cases in which the branch point is located more than 40 nucleotides from 3’ splice site, is 
functional and is essential for the regulation of alternative splicing (Smith et al., 1989). 
Generally, the mutation of the adenine residue involved in the lariat formation strongly 
reduces splicing efficiency of the downstream exon (Reed and Maniatis, 1988).
• RNA secondary structure
The cw-acting elements regulating constitutive and alternative splicing interact with 
trans-acting factors. The secondary structure that pre-mRNA creates might directly 
influence this kind of interaction.
Many studies have proposed RNA secondary structure as a regulator of alternative 
splicing. In the case of rat calcitonin/CGRP pre-mRNA splicing, the 3’ splice acceptor of 
exon 4 forms a stable stem-loop structure. Mutations that destabilize the stem abolish the 
use of this splice acceptor site in vitro (Coleman and Roesser, 1998). In the flbronectin 
EDA exon there is both an ESS and an ESE. Functional studies coupled to secondary 
structure analysis suggest that the role of the ESS element may be exclusively to ensure 
proper RNA conformation and raise the possibility that the display of the ESE in a loop 
position may represent a significant feature of the exon splicing regulatory region (Muro 
et al., 1999). An example of 5’ splice site mutation that affects a stem-loop structure can 
be found in the tau gene. In this case the disruption of secondary structure increases exon 
10 inclusion and this results in the production of an aberrant protein isoform that leads to 
neurodegeneration (Grover et al., 1999).
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• Enhancers and silencers
Additional intronic and exonic sequences are often necessary for efficient and accurate 
choice of the correct splice site. These sequences can either promote (enhancers) or 
repress (silencers) splice site usage.
SR proteins bound to splicing enhancers are thought to function by recruiting components 
of the splicing machinery to the nearby intron (Reed, 1996). Most splicing enhancers are 
located within 100 nucleotides of the 3’ splice site and are not active when located further 
away (Tian and Maniatis, 1994). However in Drosophila melanogaster doublesex pre- 
mRNA, the dsx enhancer element functions when located 300 nucleotides downstream of 
the regulated 3’ splice site (Tian and Maniatis, 1993). Recent studies show that the 
activity of splicing enhancers decreases as a function of distance from the 3’ splice site. 
Most of the enhancer elements obtained contained extended purine-rich sequences (more 
than 65% purine rich), but a second, novel class of sequences lacking stretches of purines 
was also identified (Tian and Kole, 1995). In fact, Schaal and Maniatis recently identified 
pyrimidine-rich enhancers that are more than 67% pyrimidine-rich and function such as 
strong enhancers (Schaal and Maniatis, 1999).
In addition to sequences that promote exon inclusion, there are sequences that inhibit 
splicing; exonic or intronic splicing silencers. The silencers are less well characterised; 
they can be purine or pyrimidine-rich and bind a diverse array of proteins (Fairbrother 
and Chasin, 2000). A negative element (CAGG) involved in the down regulation of 
fibronectin EDA exon inclusion was identified within EDA exon (Caputi et al., 1994), 
where it seems to be a determinant for RNA conformation (Muro et al., 1999). An 
example of an intronic splicing silencer is described for CFTR exon 9 alternative
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splicing. This extended region in intron 9 acts as a silencer by recruiting SR proteins 
(Pagani et al., 2000).
2.4.2 Trans-Acting Factors
The trans-acting factors that regulate alternative splicing are members of at least two 
protein families. The most important one is the SR protein family and the other is the 
hnRNP protein family. This last group of proteins is associated with newly synthesised 
pre-mRNA as well as mature mRNA during nucleo-cytoplasm transport. They can act on 
splicing by affecting correct spliceosomal assembly.
• SR proteins as alternative splicing regulator
Besides their role in constitutive splicing, SR proteins can also regulate alternative 
splicing either by altering the 5’ or 3’ splice site choice in pre-mRNA containing 
competiting sites (Bai et al., 1999; Krainer et al., 1990). Enhancer-bound SR proteins can 
promote the utilisation of a downstream 5’ splice site and this activity may involve the 
recruitment of U1 snRNP to the splice site (Eperon et al., 1993). In the presence of 
competing 5’ splice sites, different SR proteins show distinct preferences for promoting 
the use of proximal or distant splice sites. High concentrations of ASF/SF2 and SC35 
proteins promote the use of 5’ splice site proximal to the 3’ splice site, while SRp40 and 
SRp55 promote the use of distal sites (Zahler et al., 1992).
There are different components that determine the effect of SR proteins in the regulation
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of splite site choice; one of these is the level of their expression (Hofmann and Wirth, 
2002).
• hnRNP as a splicing regulator
hnRNP were first described as a major group of chromatin-associated RNA-binding 
proteins. These proteins contain RNA-binding motifs that possess different RNA 
sequence binding preferences (Dreyfuss et a l , 1993). In human hnRNP complexes more 
than 30 proteins have been identified and traditionally their principal function was 
described as packaging of nascent pre-mRNAs in order to protect and organise them in a 
nucleosome-like structure. In recent years a more dynamic role of hRNP proteins has 
been suggested. These proteins may be viewed as a subset of the trans-acting factors 
involved in pre-mRNA processing and some of them also act in nucleus-cytoplasm 
mRNA export (Krecic and Swanson, 1999; Weighardt et al., 1996).
Several intronic splicing enhancers and repressors associate with hnRNPs. One of the 
best-analysed hnRNP proteins is hnRNP Al. It was observed that in splicing extracts the 
relative ratio between Al and the SR protein SF2/ASF determines the usage of duplicated 
5’ splice sites in a p-globin construct (Mayeda et al, 1994).
Another well-studied protein of this family is hnRNP I, best known as PTB 
(Polypyrimidine Tract Binding Protein). This protein is involved in the regulation of 
alternative splicing of several genes. PTB recognises as its optimal binding site, the RNA 
sequence UCUU within a polypyrimidine rich context (Singh et al, 1995) that 
sometimes overlaps with U2ASF binding site and simple competition could account for 
the inhibitory action of PTB.
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Part 3. Set-up of Project
From this review it is clear that a series of problems exist relating to NF1 and need to be 
addressed.
1. Molecular Diagnostics: Although the application of the use of a cascade of techniques 
allows a useful mutation detection rate, the extremely time-consuming nature of the work 
makes them impractical for routine clinical or scientific work. An alternative strategy 
based on automated sequencing techniques would clearly be a more sensitive and 
informative method for mutation testing. However these techniques are not widely used 
as a first screen since analysis of the results can be both cumbersome and time- 
consuming, and with current methodologies raw sequence data often requires extensive 
manipulation before analysis. The Cambridge Molecular Genetics laboratory have 
previously described a novel analytical approach, comparative sequence analysis (CSA) 
to overcome this problem (Mattocks et a l , 2000). Analysis software associated with 
automated DNA sequence generates a single electrophoretogram comprising four 
different coloured traces, each representing a different base. Interpretation of this data 
then requires manual checking of each individual base and comparison with the 
equivalent base in a known 'normal' sequence. CSA splits the sequence data into its four 
component traces, each representing the distribution of a single base within the sequences 
fragment. Each of these four traces are then overlaid on the corresponding 'normal' trace 
and mutations clearly stand out as peaks with no analogous partner in the 'normal' trace- 
Figure 8
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Figure 8 Example of mutation detected by CSA. Normal sequence indicated in black, test sample indicated in colour. The base 
represented by each track is indicated in the top left of each panel. A heterozygote point mutation is seen C>T. The half-height 
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Point mutations are shown by half height 'normal' peak at the site of the mutation 
together with a new 'stand alone' peak in one of the other tracks representing the mutated 
base. Insertions and deletions are indicated by the same motif but in this case all down 
stream peaks (reading from left to right) are offset by the number of bases affected; to the 
left for deletions and to the right for insertions- Figure 9. This technique allows 
automation of data analysis where a programme can read the peak position and height for 
each base and differences highlighted, with accurate analyses of 96 lanes therefore 
achievable in minutes. Mosaic mutations may also be picked up if automation is not 
used. In this project I apply this technique to the problem of NF1 gene mutation analysis 
and the underlying mechanism of the related disorder, NFNS.
2. Recognition of splicing mutations: The high incidence of mutations that affect splicing 
in NF1 (50%) is a further point that emerges from this review (Ars, et al 2000; Messiaen, 
et al 2000). These mutations might have been previously erroneously only classified as 
nonsense, missense, frameshift or even silent mutations. The concern that diagnostically 
relevant mutations were slipping through the net because their effect on the splicing 
process had not been considered is addressed in this project. In general terms, studies to 
investigate the functional effects of sequence variations can be overlooked in the rush to 
catalogue genomic sequences, and a technique to assess this is developed. I test the use of 
a minigene splicing assay that would not need extraction of RNA from patients but 
instead uses DNA readily available to the lab, by looking at particular mutations. The 
mechanism by which each sequence change affected the gene was studied and potential 
methods for correction of defect are investigated.
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ADi
2 bp deletion
Figure 9. Frame shift mutations in CSA. The same two indicators are seen at point 
of mutation, and downstream bases are offset by number of bases involved.
MATERIALS AND METHODS
4.1 MATERIALS
4.1.1 Chemical reagents
General chemicals were purchased from Sigma Chemical Co., or Merck.
4.1.2 Enzymes
Restriction enzymes were from New England Biolabs, Inc, USA or Roche, Germany. 
DNA modifying enzymes such as T4 polynucleotide kinase, Klenow fragment of E.coli 
DNA polymerase I, T4 DNA polymerase and T4 DNA ligase were obtained from New 
England Biolabs, Inc. Taq Polymerase was from Qiagen, Germany. Calf intestinal 
alkaline phosphatase was from Roche, Germany. RNAase A was purchased from Sigma 
Chemicals. A lOmg/ml solution of RNAase A was prepared in sterile water and boiled 
for 10 minutes to destroy trace amounts of DNAase activity. All enzymes were used 
following manufacturer instructions.
4.1.3 Synthetic oligonucleotides
Synthetic DNA and RNA oligonucleotides were purchased from Sigma-Genosys. The 
pellets were resuspended in MilliQ water to obtain a concentration of 1 jig/pl.
The oligonucleotides used in this work are (bases in bold represent the relevant restriction
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enzyme sites or the base mutated to achieve complementarity/site directed mutagenesis):
• NFl/exon3(NdeI): sense 5'GG AATTCCATATGTCAAGATTCTGGTACAGGTC3'
antisense 5'GGAATTCATATGTCTCAAGGTAACATCTATCC3'
• Oligo pUC 19: sense 5TAAAACGACGGCCAGT3'
antisense 5’ACAGCTATGACCAT3f
• Ori insert: sense 5'AGCGTTATGGCCATGATGTTGTC3’
antisense 5’GATCAACAACAATAGTCTTCCAT3’
• Oligo PTB: sense 5'CAACTTCAACTCCTAAGCCACTGC3'
antisense 5’ TAGGATCCGTCACCAGGAAGTTGGTTAAATCA3'
• Oligo snRNP U 1: sense 5'GATCTCATAGTTACCTGGCAGGGGAGATACCAT3'
antisense 5’GATCATGGTATCTCCCCTGCCAGGTAACTATGA3’
• Oligo NF 1/exon 3 wild-type -2G>A: sense 5'GTCTTGCTGAGGTAAGTAAATTG3'
antisense 5' ATTTACTTACCTCAGCAAGAC3'
• Oligo NF 1/exon 3 G>C,-2G>A: sense 5'GTCTTGCTGAGGTAACTAAATT3'
antisense 5' ATTTAGTTACCTCAGCAAGAC3'
•  Oligo NF 1/exon 3 wild-type -2G>T: sense 5’ GTCTTGCTGTGGTAAGTAAATTG3'
antisense 5’ ATTTACTTACCACAGCAAGAC3'
•  Oligo NF 1/exon 3 G>C,-2G>T: sense 5’ GTCTTGCTGTGGTAACTAAATT3'
antisense 5'ATTTAGTTACCACAGCAAGAC3'
• Nfl/exon37 (Bam Hl/Xho I):
sense 5'ACGTGGATCCATGGAAGAGACCAAGCAAGTnTGA3' 
antisense 5' TGCACTCGAGTCACTTGTCATTGAATATACGGAGA31
• NF1 exon 37 sequencing: sense 5TGTATTAGCAAACGAGTGTC3'
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5'GTGCAAGTGTCTGGACCAGTGG3' 
5'CCAGTGGACAGAACTAGCTC3' 
5'CCTTGGAAACAGTCACAGAAGC3' 
5'GCTAGCTACCAAGATCACCA3' 
antisense 5TCCTTAATGAAGTAATCAGAG3'
• Oligo external NF 1/exon 37: sense 5'GCTAGCTACCAAGATCACCA3'
antisense 5'ACAGTACTTGGCAATAGCAGATAA3'
• Oligo A6791T: sense S'CCTGACACTTTCAACAGTCAAGTTCS'
antisense 5'GAACTTGACTGTTGAAAGTGTCAGG3'
• Oligo A6793T: sense S'CCTGACACTTACTACAGTCAAGTTCS'
antisense S'GAACTTGACTGTAGTAAGTGTCAGGS'
• Oligo A6794T: sense S'CCTGACACTTACATCAGTCAAGTra’
antisense 5’GAACTTGACTGATGTAAGTGTCAGG3’
• Oligo C6795G: sense 5'CCTGACACTTACAAGAGTCAAGTTC3'
antisense 5'GAACTTGACTCTTGTAAGTGTCAGG3'
Oligo C6792T/A6793T: sense 5'CCTGACACTTATTACAGTCAAGTTC3'
antisense 5'GAACTTGACTGTAATAAGTGTCAGG3'
• Oligo C6792T/A6794T: sense 5’CCTGACACTTATATCAGTCAAGTTC3'
antisense 5'GAACTTGACTGATATAAGTGTCAGG3'
• Oligo pcDNA3: sense 5’AC AG AAGCTTTGTTGG AG ATC3 ’
antisense 5'ATTTAGGTGACACTATAGAATAG3'
• Oligo exon 28-Nde: sense 5'GGGAATTCCATATGGAGATTTGTCTCTTCTC3,
antisense 5’ GGGAATTCCATATGCCTTACGTGACATTTTATAC3'
• Oligo exon 6-Nde: sense 5'GGGAATTCCATATGGGATAGATCAAGATAGCTC3'
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antisense 5'GGGAATTCCATATGCCTCTGCCAAATAAAATTATG3'
4.1.4 Plasmid constructs
4.1.4.1 Commercial plasmids used
The plasmid used in this work was pUC19 (New England Biolabs), the cloning vector 
which consists of 2686 basepairs. It contains a polylinker sequence of 54 bp within a lac 
Z gene. It contains an ampicillin resistance gene.
4.1.4.2 Minigene system construct
This system allows the pre mRNA splicing reaction to be studied. In all cases, except the 
exon 37 studies, a modified version of the EDB a-globin-fibronectin minigene was used 
(Muro et al., 1999). The EDB exon subject to alternative splicing is removed to create an 
insertion site for the sequence of interest and is represented by a unique Nde I cleavage 
site. For the exon 37 studies pcDNA3 (Invitrogen) was used linearised with BamHI and 
Xho I enzymes.
4.1.5 Bacterial culture
The K12, E. coli family strain DH5a was used for transformation by plasmid and growth 
of the plasmid.
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They were maintained in the short term as single colonies on agar plates at 4°C and for 
longer term storage were kept as glycerol stocks, made by adding sterile glycerol to a 
final 15% v/v. Glycerol stocks were stored at -20°C. An overnight culture of bacteria was 
grown in LB medium.
LB: Luria-Bertani medium per litre:
Difco Bactotryptone 10 g, Oxoid yeast extract 5g, NaCl lOg, pH 7.5.
Bacterial growth media were sterilised before using by autoclaving. The appropriate 
antibiotic, ampicillin, was added to media to a final concentration of 200 pg/ml.
4.1.6 Cell culture
The following cell lines were used:
Hep3B; human, hepatocellular carcinoma, fibroblast-like.
HeLa; human, cervix, epithelial, adenocarcinoma.
Cos 7; cercopitheous aethiops (Monkey, African green), kidney; SV40 transformed, 
fibroblast-like.
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4.2 METHODS
4.2.1 Nucleic Acid Preparations
4.2.1.1 Small-scale preparation of plasmid DNA from bacterial cultures
Purification of small amounts of recombinant plasmid DNA was performed using the 
Qiagen miniprep kit, following the manufacturer's instructions. The procedure is based on 
alkaline lysis of bacterial cells followed by adsorption of DNA onto silica in the presence 
of high salt concentrations. After washing and elution of plasmid DNA the final pellet 
was resuspended in 50 pi of dH20 and 5 pi of such preparations were routinely taken for 
analysis by restriction enzyme digests.
4.2.1.2 Large-scale preparations of plasmid DNA from bacterial cultures
For large-scale preparations of plasmid DNA, the Qiagen Midi kit was used following 
manufacturers instructions. This was achieved with overnight inoculum of 200mls using 
LB medium. The protocol is based on a modified alkaline lysis procedure, followed by 
binding of plasmid DNA to a Qiagen Anion-Exchange resin under appropriate low-salt 
and pH conditions. RNA, proteins, and low-molecular weight impurities were removed 
by a medium-salt wash. Plasmid DNA was eluted in a high-salt buffer and then 
concentrated and desalted by isopropanol precipitation. The concentration of DNA 
produced was quantified using mass spectrometry and stored at -20°C.
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4.2.1.3 Preparation of RNA from the cultured cells
RNeasy kits (Qiagen) were used to isolate total RNA from cultured cells. This technology 
uses a silica-gel-based membrane to bind RNA. The cells are first lysed and homogenised 
in the presence of a highly denaturing guanidine isothiocyanate (GITC)-containing 
buffer. Ethanol is added to provide appropriate binding conditions, and the sample is 
applied to an RNeasy mini column where total RNA binds to the membrane. The 
manufacturers protocol was followed throughout. The RNA is eluted in water and stored 
at -80°C.
The RNA quality was checked by electrophoresis on 0.8% agarose gels and the RNA 
concentration quantified by mass spectrometry.
4.2.1.4 cDNA synthesis from RNA
First strand cDNA was synthesised using a Moloney Murine Leukemia virus (M-MulV) 
reverse transcriptase kit from Amersham. Preassembled bulk first strand cDNA reaction 
mixes, DTT and pd(N)6 primer were used. The manufacturer's instructions were 
followed: the RNA solution was heated to 65°C for 10 minutes and chilled on ice, and the 
appropriate volume of reaction mix, DTT, primer was added. The mixture was incubated 
at 37°C for 1 hour. 1.5-3 pi of the cDNA reaction mix was used for the PCR analysis.
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4.2.1.5 Agarose gel electrophoresis
Gels for DNA were prepared by dissolving agarose (Sigma) in hot TBE buffer at 
concentrations of 0.8-2% (w/v) and adding 0.5pg/ml ethidium bromide (Sigma). The 
resulting solution was left to set (30 min, rt). DNA samples were mixed with one-quarter 
volume gel loading solution (Sigma) before being loaded into the gel and 
electrophoresed. DNA was visualized under UV transillumination
4.2.2 Estimation of Nucleic Acid Concentration
4.2.2.1 Spectrophotometric
An optical density of 1.0 at 260 nm is roughly equivalent to a concentration of 50 pg/pl 
for double stranded DNA, 33 pg/jil for single stranded DNA and 40 pg/pl for RNA 
samples. The ratio of values for optical densities measured at 260 nm and 280 nm is 1.8 
for pure sample of DNA and 2 for RNA. These are reduced by protein contaminants and 
therefore the values were used to assess both the concentration and the purity of the 
samples.
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4.2.3 Enzymatic Modification of DNA
4.2.3.1. Restriction enzymes
Restriction endonucleases recognise and cut within specific sequences of double stranded 
DNA leaving blunt ends, or 5’ and 3’ protruding ends. These were used in the 
construction and analysis of recombinant plasmids. Each restriction enzyme functions 
optimally in a buffer of specific ionic strength. All buffers were supplied by the same 
company that supplied the enzymes and were used according with the manufacturer’s 
instructions.
For analytical digests 100-500 ng DNA were digested in a volume of 10-20 pi containing 
5 U of the appropriate restriction enzyme per pg DNA. The digest was incubated for 3-6 
hours at the optimal temperature required by the enzyme used.
Preparative digests were made of 1-20 pg DNA using the above conditions but a larger 
reaction volume. Enzymatic activity was then removed either by incubation at 75°C for 
20 minutes or phenol-chloroform extraction.
4.2.3.2. Large fragment of E. Coli Polymerase I
The large fragment of DNA Polymerase I (Klenow) lacks the 5’ to 3’ exonuclease 
activity of the intact enzyme, but retains 3’ to 5’ exonuclease activities. It is used to 
catalyse the polymerisation of deoxyribonucleotide triphosphates in a 5’ to 3’ direction 
on a template of double stranded DNA with a recessed 3’ hydroxyl and protruding 5’
80
phosphoryl terminus to generate a flush-ended DNA molecule. This was useful for 
creating compatible ends for ligation during construction of recombinant plasmids and to 
digest specific A residues added by Taq DNA polymerase at the 5’ terminus.
Klenow fragment was used with the proper buffer supplied by New England Biolabs Inc. 
at a final concentration of 5 U per pg DNA. When a “fill-in” was required (DNA 
fragments with protruding 3’ ends) dNTP with a final concentration of 0.5 mM were 
added. The mixture was incubated at 37°C for 20 minutes.
4.2.3.3 Dephosphorylation of DNA 5’ termini
Calf intestinal phosphatase catalyses the removal of 5’ terminal phosphate groups from 
linear DNA molecules. This is used to reduce self-ligation of vector DNA during 
generation of recombinant clones, thus increasing the proportion of resulting 
recombinants containing the required DNA inserts.
This reaction was carried out in a final volume of 50-100 pi using 1U of enzyme per 0.5 
pg DNA incubating for 1 hour at 37°C. The enzyme was then inactivated by adding 1 
mM EDTA and incubating for 20 minutes at 75°C.
4.2.3.4 T4 DNA ligase
T4 DNA ligase catalyses the formation of a phosphodiester bond between adjacent 3’ 
hydroxyl and 5’ phosphoryl termini in DNA, requiring ATP as a cofactor in this reaction. 
This enzyme was used to join double stranded DNA fragments with compatible sticky or
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blunt ends, during generation of recombinant plasmid DNA.
20 ng of linearised vector were ligated with a 5-10 fold molar excess of insert in a total 
volume of 20 pi containing lx ligase buffer and 1 U T4 DNA ligase. The reaction was 
carried out at room temperature for 3-4 hours in most cases and at 16°C for blunt- ended 
ligations.
4.2.4 Elution and purification of DNA fragments from agarose gels
This protocol was used to purify small amounts (less than 1 pg) of DNA for subcloning. 
The DNA samples were loaded onto an agarose minigel and electrophoresed as described 
10.2.1.5.
The DNA was visualised with UV light and the required DNA fragment band was 
excised from the gel. A Gel Extraction kit was used (Qiagen, Germany). This kit uses a 
silica-membrane to adsorb DNA from agarose gel in the presence of high salt 
concentrations while contaminants pass through the column. The DNA is eluted with Tris 
buffer or water. The manufacturer's protocol was followed.
4.2.5 PCR reactions
4.2.5.1 PCR reactions for cloning purposes.
The polymerase chain reaction was performed on genomic or plasmid DNA following the 
basic protocols of the Boehringer and Promega Taq DNA Polymerases. The volume of 
the reaction was 50-100 pi with lx Taq buffer, dNTP mix 200 pM each, oligonucleotide
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primers 100 OOnM each, Taq DNA Polymerase 2.5-5 U. 0.1 ng for plasmid and 100 ng of 
genomic DNA were used for amplification. The amplification conditions varied for each 
particular PCR but normally comprised a hot start (94°C, 3 min) followed by the 
denaturing step (94°C, 1 min), annealing (45-65°C, 1 min) and extension (72°C, 1 min) 
The denaturing-annealing-extension cycle was repeated 30-35 times. The amplifications 
were performed on a ThermoHybaid PCR Express or PTC-100 programmable thermal 
controller.
4.2.5.2 PCR reactions for mutation analysis
Genomic DNA was extracted from peripheral blood using the Nucleon BACC2 kit and re 
suspended in TE buffer to a concentration of approximately 500|ig/ml. The entire reading 
frame of the NF1 gene was PCR amplified exon by exon, in a total of 58 amplicons. In 
general primers were designed so that each amplicon comprised an exon flanked by at 
least 50 base pairs of intron on either side. One primer in each pair was tailed with an 
M13 primer sequence (M13F: TGTAAAACGACGGCCAGT or M13R: CAGGAAACA 
GCTATGACC) to provide a binding site for M l3 universal sequencing primer. Care was 
taken to ensure that any repetitive sequences flanking the exon lay at the opposite end of 
the amplicon with respect to the M13 sequencing primer sequence. In general the PCR 
temperature profile was: Initial denaturation at 95°C for 2 minutes, followed by 30 cycles 
with annealing for 30 seconds, elongation at 72°C for 1 minute, and denaturation at 95°C 
for 30 seconds. Primer sequences, annealing temperatures and buffers used are given in 
Table 3.
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Table 3: Primers and conditions for NF1 PCRs.
Forward primer Reverse primer Lengtli Ta Buffer Seq
Primer
Orientation
1F.A AGACCCTCTCCTTGCCTCTT 1R0 M13RX - ATGGAGGGTCGGAGGCTG 458 55.0 D M13R Reverse
2F.1 TGGCAAGTAAGTTATTTATGGTC 2R1 M13F-AATCAAAAAGAAAAGAAAGCAA 288 55.0 B M13F Reverse
3F.1 GTTTGCCTTAGACTTTAGTTTTT 3R1 M13F-CATCTGTACTTTGGGACATAA 368 55.0 B M13F Reverse
4aF.O nTGAAAATTTTCATAATAGAAAATGT 4aR.O M13RX - GGTCAAAGCTGCTGTGAG 435 55.0 C M13R Reverse
45F.0 M13FX - TCCTGGCCTCAAGTGGTC 4bR0 M13RX - TTATAAAANCCAGATTGGTGTTC 386 57.0 B M13F Forwarcl
4cF.O M13FX - TCCTAGCAGACAACTATCGA 4cR.O AAAAAAAAATCAATCGTATCCTTA 582 55.0 C M13F Forward
6F.0 M13FX - CAIG ITI'A ICTTTTAAAAATGTTGCC 6R0 ATAATGGAAATAATTTTGCCCTCC 323 55.0 c M13F Forward
7F.0 M13FX - TGCTATAATATTAGCTACATCTGG 7R0 CCTATGAACTTATCAACGAAGAG 395 55.0 B M13F Forward
8F.0 M13FX - TTGTGTGGGTAATGTGTTGA 8R0 AAATATAGTTAGATAAAAACCAATG 270 55.0 B M13F Forward
9F.1 TATTTGCTGTTC1111IGG 9R1 M13F - AATTTAGCAATACCTTTTGG 204 55.0 B M13F Reverse
9aF.O TCCGCTGTGGCTCAGAACAC 9aR.O M13RX - AGTAGAAGAGGATGCACAGCC 315 60.0 B M13R Reverse
10aF.0 M13FX - GATAAACAGAGCATACAACTCA 10aR.0 AAATGCAATAGAAAGGAGGTGA 270 55.0 B M13F Forward
10bF.A AACTATTGAGTGTTCTACTATACC 10bR0 M13RX- TTGGCGATTCAGCTAAACC 374 55.0 G M13R Reverse
10cF.1 W13F - CGTCCAGCCTAGTTCTAGAA 10cR1 ACCCCIICIIICICCAI 444 55.0 C M13F Forward
11F.0 M13FX - ATAAGTACTCCAGTGTTATGT 11R0 TAAAGTTGAAATTTAAAAAATTAAAGTAC 179 52.0 C M13F Forward
12aF.O M13FX - AAACCTTACAAGAAAAACTAAGCT 12aR0 ATTACCATTCCAAATATTCTTCCA 325 55.0 C M13F Forward
12PF.0 M13FX - 11ICIAGTAAATCTCCTTCAAGT 12bR0 ATGAAATTTACCAAATTTCATTCAG 404 55.0 C M13F Forward
13F.1 AAGATATTTrGGGGTTTGAA 13R1 M13R - GCCATGTGCTTTGAGG 508 55.0 B M13R Reverse
14F.0 M13FX - AGCTTA7CAGGTTCTCCATTGG 15R0 M13R - AGTTAACAGACAAAAGTCAACTTTACAG 535 55.0 D M13F Forward
14F.0 M13FX - AGCTTATCAGGTTCTCCA7TGG 15R0 M13R - AGTTAACAGACAAAAGTCAACTTTACAG 535 55.0 D M13R Reverse
16F.0 M13FX - 7GGATAAAGCATAATTTGTCAAGT 16R0 TAGAGAAAGGTGAAAAATAAGAG 571 55.0 B M13F Forward
17F.0 CTGTGTGTTTAGATCAGTCA 17R0 M13RX - TTTATCAATTACTACCAGTATCAG 339 55.0 B M13R Reverse
18F.0 AGAAGTTGTGTACGTTCTTTTCT 18R0 M13RX- TCCTTTCTACCAATAACCGC 388 55.0 I M13R Reverse
19aF.O M13FX - ATCTCACTTAGGTTATCTGG 19aR0 TGTAATTAAGTAGTTATAACTCTC 290 60.0 B M13F Forward
19bF.1 M13F-ATTTGAGGGGAAGTGAA 19bR2 M13R - ATGGGTATTATTTCTTTGCT 312 55.0 E M13R Reverse
20F.0 M13FX - CATTCACACCATGCACATATGATTG 21RO M13R - GATTTGCTATGTGCCAGGCAC 703 55.0 E M13F Forward
2OF.0 M13FX - CATTCACACCATGCACATATGATTG 21RO M13R - GATTTGCTATGTGCCAGGCAC 703 55.0 E M13R Reverse
22F.0 M13FX ■ TGCTACTCTTTAGCTTCCTAC 22R.0 ACAGCGGTTCTATGTGAAAAG 537 55.0 B M13F Forward
23-2F.0 M13FX - CTTAATGTCTGTATAAGAGTCTC 23-2R0 ACTTTAGATTAATAATGGTAATCTC 290 55.0 C M13F Forward
23aF.O CAGAAATAGTATACATGATTGGGT 23aR0 M13RX - CTA1111CIGCCAGAATTAGTAGA 465 55.0 c M13R Fleverse
24F.0 M13FX - TTGAACIC11! IGTTTTCATGTCTT 24R0 GGAATTTAAGATAGCTAGATTATC 289 55.0 c M13F Forward
25F.0 M13FX - AATATAATAATTATATTTGGGAAGGT 25R.0 GAAAATATTTGATTCAAACAGAGC 360 55.0 B M13F Forward
26F.1 M13F - CCCTCCATATTTGTAATCTT 26R.1 TTAAACGGAGAGTGTTCAC 324 58.0 B M13F Forward
27aF.1 AGGGCATTTTAATCTnTAT 27aR1 M13F - GCAAACTCTCCTTCTCAAC 406 55.0 F M13F Reverse
27bF.1 M13H - GCCAAATTACCCTTTAGAATG 27bR.1 AACCAAACTTGCCATCTCT 348 55.0 C M13R Forward
28F.1 M13F- GACTTTGAAGAAITG111IATA 28R0 M13RX - CTATAGGGGTAGGACACC 693 55.0 E M13F Forward
28F.1 M13F - GACTTTGAAGAATTGTTTTATA 28R0 M13RX - CTATAGGGGTAGGACACC 693 55.0 E M13R Reverse
29F.1 M13F- TACAATGGTGGGAACTCTTCCTTA 29R.0 M13RX - ACCAACACTGCATACCTTCCAATT 635 55.0 E M13F Forward
29F.1 M13F - TACAATGGTGGGAACTCTTCCTTA 29R0 M13RX - ACCAACACTGCATACCTTCCAATT 635 55.0 E M13R Reverse
30F.0 GCCTCACAGTGCTCTTATGG 3OR.0 M13RX - CCTTCAGAGTTCCTTCAGTTAC 628 55.0 C M13R Reverse
31F.0 TGTTGATGTGATTTTCATTGACCA 31 RO M13RX - CCAATGTGGCACCAGATAAATAT 337 55.0 B M13R Reverse
32F.0 M13FX - ATCTAGTATTTTTGAGGCCTCAG 32R0 CAGATATGCTATAGTACAGAAGG 334 55.0 C M13F Forward
33F.0 M13FX - TATCTGTTTTATCATCAGGAGG 33R1 M13R - TAAAATGGAGAAAGGAACTCG 497 55.0 E M13R Reverse
34F.1 M13F- AAAATGAAACATGGAACTTTAG 34R0 M13RX - TAAGCATTAAGTACAAAATAGCAC 439 55.0 E M13F Forward
35F.0 ATGTATTCAGAGTATCCCCTT 35R0 M13RX - ATTTAAACGTCTTTTAGAAAAATG 458 55.0 C M13R Reverse
37F.0 M13FX - ATTCCGAGATTCAGTTTAGGAG 37R0 AGTAACATTCAACACTGATACCC 256 55.0 H M13F Forward
38F.1 ACATGGGTAATTTAGGAAGATAAG 38R1 M13F- CAACAAGAAAAGATGGAAGA 335 55.0 C M13F Reverse
39F.0 CTACTGTGTGAACCTCATCAACC 39R.0 M13RX - GTAAGACATAAGGGCTAACTTACTTC 306 55.0 !T T " M13R Reverse
4OF.0 GGGAAGAAGAGCTCAGCAGAT 40R.0 M13RX - AACTTTCTGCTCTGCCACGCA 345 55.0 t M13R Reverse
41F.0 TTCATCCTGTTTTAAGTCACACTTG 41R.0 M13RX - TTGCCTCCATTAGTTGGAAAATTG 295 55.0 H M13R Reverse
42F.0 GAAGGAGCAAACGATGGTTG 42R.0 M13RX - AAACTTTGCTACACTGACATGG 371 55.0 C M13R Reverse
43F.0 GTATTAGAGCTTTCTTTGAGTC 43R.0 M13RX - GAATCGTAGAGTTTATCTTTTG 421 55.0 C M13R Fleverse
44F.2 M13R - GGTGAAGTGATTATCCAGGTG 44R.2 TGTTATCTGTTTGGGTGAGAAG 328 55.0 E M13R Forward
45F.0 M13R - AGATAACAATTCAGCCACAAAG 46R.0 TAAAGACAGGCACGAAGGT 225 55.0 F M13R Forward
46F.1 M13R - ATTTTGGCACATTATTCTGG 46R.1 GCGCATGTTAGCAAGTT 316 55.0 C M13R Forward
47F.0 CTGTTACAATTAAAAGATACCTTGC 47R.0 M13RX - GTGTTCTTAAAGCAGGCATAC 204 55.0 H M13R Reverse
48F.0 TTTTGGCTTCAGATGGGGATTTAC 48R0 M13RX - AAGGGAATTCCTAATGTTGGTGTC 373 55.0 B M13R Reverse
48aF.O ATCTAGTATCTAATTGTATTTCACCC 48aR0 M13RX- AGACTGAGCTTACAGGGAC 265 55.0 A M13R Reverse
49F.0 M13FX - CTGGGAGAAACAGGCTATAC 49R.0 CACIIICI11GCAGTTGTTCTG 639 58.0 E M13F Forward
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4.2.6 Sequence analysis
4.2.6.1 Sequence analysis for plasmid DNA
Sequence analysis of plasmid DNA and inserts was performed by the sequencing facility 
of the Cambridge University Biochemistry Department, using ABIprism sequencing 
machines (Perkin Elmer).
4.2.6.2 Sequencing for NF1 mutation analysis
PCR products were purified by adding 1 U shrimp alkaline phosphatase (Amersham) and 
10U exonuclease I (NEB) to each reaction and incubating at 37°C for 30 min followed by 
95°C for 10 min to denature the enzymes. Purified PCR products were then sequenced in 
a single orientation dependent on the location of the M l3 tail on the PCR primers. 
Reactions comprised 2 pi of PCR product, 0.7 pi BigDye V sequencing reaction mix 
(Applied Biosystems), 1.05 pi 5x sequencing diluent (Applied Biosystems), 0.35 pi 
primer at 10 pmol/pl, 5% (v/v) betaine (Sigma) and ddH20 to 7pl. Initial denaturation 
was at 95°C for 5 min, followed by 25 cycles with annealing at 50°C for 15 sec, 
elongation at 60°C for 4 min, and denaturation at 95°C for 30 sec. For batches D02 and 
D04 completed sequencing reactions were purified using Dynapure™ Dye Terminator 
Removal Ver.2 (Dynal A.S, Oslo, Norway) according to the manufacturer's protocol. 
Products were resuspended in 1.5 pi formamide and 0.8 pi of this was dotted on 96 well 
RapidLoad™ membrane combs (Web Scientific Crewe, UK). The ABI 377 was loaded
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using the ‘water protocol’ as described by Web Scientific. For batch D05 four plates of 
sequencing reactions were transferred to a single Multiscreen 384 well filter plate 
(Millipore, Bedford, UK) and purified according to the manufacturer's protocol. The 
samples were then re suspended in 15 pi Hi-Di formamide (Applied Biosystems) with 
0.05 pi GeneScan™ 500 LIZ size standard (Applied Biosystems) per reaction and 
transferred to a 384 MicroAmp optical plate (Applied Biosystems) for loading on the ABI 
3100.
4.2.6.3 Sequence analysis
Analysis was carried out using an automated comparative sequence analysis (CSA) 
programme AutoCSA12. This is described in (Mattocks, et al 2004). In brief, the 
technique involves horizontal alignment of each of the four base traces separately with a 
control trace. The programme then calculates peak position and height for each base and 
will highlight all differences. No electrophoretograms were examined directly unless 
variations were called by the programme. Called variations were examined in GeneScan 
V3 (Applied Biosystems) by non-automated CSA (Mattocks et al, 2000). For batches 
D02 and D04 horizontal alignment was achieved by generating an artificial size standard 
applying arbitrary numbers to the peaks in one of the four traces (usually red C trace). As 
a fifth color became available batch D05 was horizontally aligned using the GeneScan™ 
500 LIZ size standard. Sequence variations were confirmed by re-sequencing using a new 
aliquot of DNA.
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4.2.7 Site directed mutagenesis
Site directed mutagenesis involved the substitution of a specific nucleotide by another. 
Synthetic mutagenic oligonucleotides are used for this method. Details of the primers 
used are listed in section 4.1.3.
4.2.8 Pull-down analysis-procedure of affinity purification of RNA-bound proteins
This was performed by Dr E Buratti at International Centre of Genetic Engineering and 
Biotechnology (ICGEB), Italy. His methods are described below.
4.2.8.1 Preparation of RNA templates for pull-down analysis
RNA templates were obtained by amplifying the respective exon/intron sequences using 
a forward primer carrying a T7 polymerase target sequence
(5TACgTAATACgACTCACTATAg3') with 12 nucleotides complementary for the 
specific exon and a reverse primer carrying 18 nucleotides of the target sequence. The 
amplified products were then purified and approximately ljig of DNA was transcribed 
using T7 RNA polymerase (Stratagene) as described elsewhere (Buratti and Baralle, 
2001).
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4.2.8.2 Purification of RNA-bound protein complexes
500 pmole of RNA (approx. 15pg of T7 RNA polymerase-synthesized 100-mer RNA) 
are placed in a 400pl reaction mixture containing lOOmM NaOAC pH=5.0 and 5mM 
sodium m-periodate (Sigma), incubated for 1 hour in the dark room at room temperature, 
ethanol precipitated, and resuspended in lOOpl of 1.0 M NaOAC, pH 5.0. The RNA was 
mixed with 300pl of adipic acid dehydrazide agarose bead 50% slurry (Sigma) 
equilibrated in lOOmM NaOAC pH 5.0 (with four 10ml washes) and the mix was 
incubated for 12 hours at 4°C on a rotator. The beads with the bound RNA were pelleted, 
washed 2 times with 1ml 2M NaCl and then 3 times with 1ml washing buffer (5mM 
HEPES pH 7.9, ImM MgCk, 0.8 mM magnesium acetate). A protein mix (in binding 
buffer: 20mM HEPES pH 7.9, 72mM KC1, 1.5 mM MgCl2 , 0.78mM magnesium acetate, 
0.52mM DTT, 3.8% glycerol, 0.75mM ATP and ImM GTP, 0.5 mg/ml heparin) 
containing approximately l-2mg of HeLa cell nuclear extract (C4, Biotech) was then 
added to the beads and incubated in a rotator for 30 minutes at room temperature. After 
incubation the beads were pelleted by centrifugation at 300rpm for 3 minutes and washed 
4 times with 1.5 ml of washing buffer before addition of SDS sample buffer and loading 
on a 10% SDS-PAGE gel.
4.2.8.3 Nanoelectrospray mass spectrometry and database homology search
Internal sequence analysis from the Coomassie blue-stained bands excised from the SDS- 
PAGE gel was performed using an electrospray ionization mass spectrometer 9LCQ
DECA XP, Thermo Finnigan). The bands were digested by trypsin, and the resulting 
peptides were extracted with water and 60% acetonitrile/1% trifluoroacetic acid. The 
fragments were then analysed by mass spectrometry, and the proteins were identified by 
analysis of the peptide MS/MS data with Turbo SEQUEST (Thermo Finnigan) and 
MASCOT (Matrix science).
4.2.9 Maintenance and analysis of cells in culture
Hep3B, Hela and Cos 7 cell lines were maintained in 100x20 mm Falcon tissue culture 
plates, incubated at 37°C and with 5% carbon dioxide. These cell lines were grown in 
Dulbecco’s modified Eagle’s medium supplemented with 4.5g/l glucose, 10% foetal calf 
serum, 50 pg/ml penicillin/streptomycin and 4 mM glutamine.
Plates containing a confluent monolayer of cells were passaged 1 in 3-5 with 1% trypsin 
as follows. Cells were washed with 5 ml PBS solution, then were incubated at 37 °C with 
1 ml PBS/EDTA/trypsin solution (PBS containing 0.02% w/v EDTA and 2% v/v trypsin 
solution) for 2 minutes or until cells were dislodged. After adding 10 ml of media cells 
were pelleted by centrifugation in polypropylene tubes and resuspended in 5ml pre­
warmed medium. 1-2 ml of this cell suspension was added to 10ml medium in fresh plate 
and was gently mixed before incubation. This procedure was required on average once 
every three days.
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4.2.10 Transfection of recombinant DNA into cells maintained in culture
Cells were passaged as above into 6-well tissue culture plates and grown to a confluency 
of 40-70%.
The transfection was performed by Effectene non-liposomal transfection reagent 
(Qiagen). The Effectene reagent was used in conjunction with the enhancer and the 
DNA-condensation buffer (Buffer EC) to achieve transfection. In the first step of 
effectene-DNA complex formation, the DNA is condensed by interaction with the 
enhancer in a defined buffer system. The reagent is added to the condensed DNA to 
produce condensed effectene-DNA complexes. These are mixed with medium and 
directly added to the cells: 1 pg of expression plasmid was mixed with O.lpg/pl of buffer 
EC to a total volume of 150pl. 8pi of enhancer was added and mixed. The mixture was 
incubated at room temperature for 2-5 min. The mixture was 25 pi effectene transfection 
reagent was added to the DNA-enhancer mixture and mixed. The samples were incubated 
at room temperature for 5-10 minutes to allow transfection-complex formation. 1ml of 
growth medium was then added to the transfection complexes and added drop-wise onto 
the cells in the 60mm dishes. These were then swirled and incubated at 37° for up to 48 
hours. The medium was then collected and the cells were washed with PBS. RNA 
isolation followed as described in section 4.2.1.3.
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4.2.11 Measurement of transfection efficiency
48 hours after transfection, the medium was collected and a colorimetric enzyme assay 
for the quantitative determination of secreted human growth hormone was performed 
using hGH ELISA reagent kit (Roche Diagnostics GmbH, Manneim, Germany). The 
200pl of diluted medium was loaded onto the microtitre plate and incubated for 1 hour at 
37°C to allow binding of the protein to the plate. The unbound proteins were then 
removed by five washings with washing buffer. A 200pi sample of anti-hGH-DIG was 
added in each well following incubation of lh at 37°. After five washings, 200pl of anti- 
DIG-POD antibody solution was added and incubated for lh at 37°C. After repeated 
washings, POD substrate was added and photometric measurements were performed at 
405nm.
4.3 Clinical methods and recruitment of patients
131 unrelated subjects were referred for NF1 mutation analysis mainly from the 
Addenbrooke’s Hospital, Cambridge but also from other centres within East Anglia. All 
patients were examined for signs and symptoms of NF1 either by personal consultation or 
by careful examination of the medical notes. 91 patients fulfilled the NIH Consensus 
development conference criteria ((NIH), 1987). Other patients without the diagnosis of 
NF1 were included in the mutation analysis to act as controls. The NFNS patients were 
recruited either from Cambridge or GOS Genetics departments and examined by myself 
(Case 6), Dr Baraitser or Dr Elmslie (all patients).
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4.4 Fundamentals of the functional minigene splicing assay
The functional minigene splicing assay is a technique using hybrid minigenes with the 
exon/s of interest inserted into it. This system allows further study of the sequence in 
question and assessment of splicing. The minigene constructs are transiently transfected 
into eukaryotic cells and the splicing products obtained by RNA extraction and amplified 
by RT-PCR using oligonucleotides specific for the region of interest. The size of the 
cDNA bands obtained when analysed by agarose gel electrophoresis will be the sum of 
bases for each exon included in the transcript. Thus a calculation is made and this 
confirms exon skipping or inclusion. The minigene sytems used in this study are: PTB (a 
modified version of the a-globin-fibronectin EDB (Muro et al, 1999; Niksic et al, 1999) 
and pcDNA3 (Invitrogen), for small and large inserts respectively. With regards to PTB, 
part of a flanking EDB exon from an intronic region (from the intronic Nde I site -1 to 
intronic Xba I site +1) has been removed. The sequence of interest is then cloned into this 
unique Nde I site created (Figure 10). Transcription of this minigene is by use of the a- 
globin promoter and the SV40 enhancer. In pcDNA3, the sequence of interest is cloned 
into the polylinker site. Transcription is through a CMV promoter (Figure 11). The 
minigene assay is shown in Figure 12.
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3a -1 Nde I +1 3b
Figure 10 The PTB minigene. The alpha globin and fibronectin 
EDB exons are represented by purple and pink boxes 
respectively. Transcription is guided by an interrupted alpha 
globin promoter and SV40 enhancer (5’ arrow). The Nde I 
restriction site used in this project is shown.
Figure 11 pcDNA 3 minigene. The sequence of interest is cloned into the area 
between restriction sites Bam HI and Xho I. Transcription is guided by a CMV 
promoter.
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Figure 12 The assay.
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4.5 Amplification of exon 3 in mutant and WT DNA and cloning into pUC19
NF1 Exon 3 with flanking 5' and 3' intronic regions was amplified using oligonucleotides 
'NF 1/exon 3 (Ndel)'. The product is 855 bp long
Figure 16 outlines the steps taken to achieve cloning of the amplicon into the PTB 
minigene system. As the patient is heterozygote for the mutation, I was able to determine 
by sequencing which clones were wild type (these were used as controls) and which had 
the exon 3 +5 G>C mutation. Sequencing also allowed checking that the entire insert 
sequence was correct and that no other base changes had been introduced during the PCR 
Taq polymerase reaction, before the insert was cloned into the PTB minigene.
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Figure 13 Cloning strategy for NF1 exon 3 in PTB and steps in the minigene assay.
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4.6 Amplification of exon 37 mutant and WT and cloning into pUC19.
NF1 exon 37 with flanking exons 34, 35, 36 and 38 with their respective introns were 
amplified using oligonucleotide NF1 exon 37 (BamHI/XhoI) sense and antisense. The 
BamHI and Xhol tails were necessary for the subsequent subcloning into pcDNA3 
minigene. The amplicon was 3280 base pairs long. In the case of exon 37, splicing was 
studied in the correct context by using the flanking exons and introns, which together 
were not too long to include in the construct. As previously described the amplicons were 
cloned into the Smal site of pUC19 and sequenced to determine mutant and wild-type 
alleles from the same heterozygote patient and to confirm that no other mutations had 
been introduced during the PCR reaction. The inserts were then removed and subcloned 
into the pcDNA3 after enzymatic digest with BamHI and Xhol for the 'functional splicing 
assay1 - Figure 19.
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Figure 14 Cloning strategy for exon 37 in pcDNA3 and minigene assay
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Results
Part 1: Mutation screening o f the NF1 gene
5.1 Sequence analysis of NF1
Mutation analysis of a gene will generate sequence variations that can generally be 
classified into the following groups: large deletions, nonsense, frameshift, missense, 
splice site or silent mutations. Classically a frameshift or nonsense sequence variation is 
thought to truncate the protein. A missense change, if thought to be pathogenic, is 
assumed to interrupt an amino acid important for the structure or function of the protein. 
And silent mutations, where the amino acid is not altered, are thought of as allelic 
polymorphisms and considered neutral.
In this study I carried out NF1 mutation screening and the sequence variants found were 
classified as pathogenic mutations if they fulfilled one of the following criteria: 
a) resulted in the introduction of a stop codon that truncated the protein e.g. frameshifts, 
and amino acid alteration to stop codon, b) affected an invariant splice consensus 
sequence, c) could be demonstrated to be de novo in the patient (i.e. not present in 
parents), d) previously reported as pathogenic in the literature and fulfilling any of the 
above or with supporting data to show that function is impaired.
In the definitely affected group putative mutations were found in 75 (82%). In the 
possibly affected group 7 mutations were found (54%). No mutations were found in any 
of the patients classified as unaffected (27). In total 73 different potentially significant
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sequence variations were found of which 57 (78%) were novel and previously 
unreported. Table 4 provides a summary of the NF1 mutations and sequence variations 
found.
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Table 4. Summary of NF1 mutations and sequence variations found
NIH Exon Mutation Type Predicted affect Accession Cf
NF 1 1-14 to 7 del Frameshift Truncated protein
21 bp
NF 2 127 del CT Frameshift Truncated protein
V65X
NF 3 271 G>A E91X Nonsense Truncated protein
NF 4a 311 T>A Nonsense Truncated protein
L104X
NF 4b 499 del TGTT Frameshift Truncated protein CD995532
D176X
NF 4c 597/8 del 23 Frameshift Truncated protein
V207X
NF 6 787 A>T Nonsense Truncated protein
K263X
NF 7 916 del G Frameshift Truncated protein
L316X
NF 7 889-2 A>G Splice acceptor Truncated protein CS991467
NF 8 1070 T>C Missense Amino acid
L357P substitution
NF 9 1246 C>T Nonsense Truncated protein CM992366 Y
R416X
NF 10a 1274 G>A Nonsense Truncated protein CM000779
W425X
NF 10a 1318 C>T Nonsense Truncated protein CM950845 Y
R440X
NF 10a 1318 C>T Nonsense Truncated protein CM950845 Y
R440X
NF 10a 1318 C>T Nonsense Truncated protein CM950845 Y
R440X
NF 10b 1527+1 G>C Splice donor Truncated protein
NF 11 1642-2 A>G Splice acceptor Truncated protein
NF 12a 1756 del ACTA Frameshift Truncated protein CD982825
I603X
NF 13 2124 del CT Frameshift Truncated protein
E715X
NF 13 2034 ins C Frameshift Truncated protein
D699X
NF 13 2180 C>G Nonsense Truncated protein
S727X
NF 15 2352 G>C Missense Amino acid substiitution
W784L
NF 16 2851-2 A>G Splice acceptor Truncated protein
NF 18 2991-4 del Splice acceptor Truncated protein
ATA
NF 19a 3163 C>T Nonsense Truncated protein
Q1055X
NF 21 3528 del A Frameshift Truncated protein
L1183X
NF 21 3546 del T Frameshift Truncated protein
L1183X
NF 22 3758 to 3762 Frameshift Truncated protein
del TCTAC
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NF 24 4265 C>A Nonsense Truncated protein
S1422X
NF 27a 4537 C>T Nonsense Truncated protein CM941093 Y
R1513X
NF 27a 4537 C>T Nonsense Truncated protein CM941093 Y
R1513X
NF 27a 4515-1 G>A Splice acceptor Truncated protein
NF 28 4913 del Frameshift Truncated protein CD972357
TCTCT
C1661X
NF 28 4950 ins A Frameshift Truncated protein
Y1650X
NF 31 5898 del GA Frameshift Truncated protein
D1987X
NF 31 5943+1 G>T Splice donor Truncated protein
NF 32 5944-1 G>C Splice acceptor Truncated protein
NF 33 6181 del 8bp Frameshift Truncated protein
D2074X
NF 34 6483 C>G Nonsense Truncated protein
Y2161X
NF 35 6641+1 del G Splice donor Truncated protein
NF 36 6709 C>T Nonsense Truncated protein CM000815 Y
R2237X
NF 36 6709 C>T Nonsense Truncated protein CM000815 Y
R2237X
NF 37 6792 C>A Nonsense Truncated protein CM981382
Y2264X
NF 37 6792 C>G Nonsense Truncated protein CM981382
Y2264X
NF 39 7096 ins A Frameshift Truncated protein
N2400X
NF 40 7206 del CA Frameshift Truncated protein
C2405X
NF 40 7201 A>T Nonsense Truncated protein
K2401X
NF 41 7285 C>T Nonsense Truncated protein CM000818 Y
R2429X
NF 42 7427 ins TC Frameshift Truncated protein
S2502X
NF 42 7486 C>T Nonsense Truncated protein CM941096 Y
R2496X
NF 45 7807 -2 A>G Splice Truncated protein
Q 12b 1994 C>T Missense Amino acid substitution CM000785
S665F
NF 12b 1885 G>A Missense Amino acid substitution CM961026 Y
G629R
NF 12b 1885 G>A Missense Amino acid substitution CM961026 Y
G629R
Q 16 2530 C>T Missense Amino acid substitution CM002379
L844F
Q 17 2970 del AAT Inframe Amino acid deletion CD931025
AM991 deletion
Q 26 4402 A>G Missense Amino acid substitution CM971049
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NF 7 1010 A>T 
E337V
Missense Amino acid substitution
NF 7 970 T>C 
C324R
Missense Amino acid substitution
NF 10b 1466 A>G 
Y489C
Missense Amino acid substitution
NF 10b 1466 A>G 
Y489C
Missense Amino acid substitution
NF 10b 1466 A>G 
Y489C
Missense Amino acid substitution
NF 10c 1595 T>C 
L532P
Missense Amino acid substitution
NF 12a 1722 C>A 
S574R
Missense Truncated protein
NF 13 2040 C>T 
C680C
Samesense Truncated protein
NF 16 2514 C>G 
I838M, 2531 
T>C L844P
Missense Amino acid substitution
NF 16 2531 T>C 
L844P
Missense Amino acid substitution
NF 16 2617 C>T 
R873C
Missense Amino acid substitution
NF 18 3113+3 ins A Intronic Truncated protein
Q 19b 3217 A>G 
M1073V
Missense Amino acid substitution
Q 21 3587 T>G 
L1196R
Missense Amino acid substitution
NF 22 3826 C>G 
R1276G
Missense Amino acid substitution
NF 22 3826 C>G 
R1276G
Missense Amino acid substitution
NF 22 3827 G>A 
R1276Q
Missense Amino acid substitution
NF 22 3827 G>A 
R1276Q
Missense Amino acid substitution
NF 24 4111-8 del 
GTT
Intronic Truncated protein
Q 24 4255 A>G 
K1419E
Missense Amino acid substitution
NF 25 4312 del 
GAAAE1438
Inframe
deletion
Amino acid deletion
NF 28 4973 del 6 
AIY1658-9
Inframe
deletion
Amino acid deletion
NF 28 5172 G>A 
K1724K
Samesense Truncated protein
NF 29 5427 C>T 
R1808R
Samesense Truncated protein
NF 39 7096 del 6 
ANF2366-7
Inframe
deletion
Amino acid deletion
Key to abbreviations used in table: NF- fulfils NF1 diagnostic criteria, Q- did not 
fulfil diagnostic criteria. Missense mutations have been included in this table, only if 
previously reported as pathogenic or in the cases of: H31R, L145P, Y489C, P533L, 
and Ml073V where non-affected parental samples did not have the same mutation.
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5.1.2 Mutation spectrum
By far the largest group of variations were single base pair substitutions, which were 
detected in 56 cases (68%). Of these 38 (68%) were transitions and 18 (32%) were 
transversions, proportions corresponding closely with those previously observed (Ars et 
al., 2000). Mutation at CpG dinucleotides account for 20/60 (33%) of the single base 
pair substitutions. Of these single base pair substitutions the most frequently detected 
single group of sequence variants were missense substitutions, which were found in 24 
subjects (28%). Of these 18 were found in patients who fulfilled the NIH criteria whilst 6 
were found in possibly affected patients. Only five of these have been previously 
described but a further 11 have closely related variations (affecting the same codon) in 
the literature. Two mutations of note were first, the variant of codon 844 (2531T>C 
L844P), which was found twice in this study and is one of at least four known variations 
of this codon. Second, the missense variant 1722 C>A S574R that affects the first base of 
exon 12a and may exert an effect by amino acid substitution or by interfering with normal 
splicing.
I also detected 21 nonsense mutations within the single base pair substitutions, of which 
16 (76%) have been described by previous investigators. In 13/21 (62%) of the nonsense 
mutations the mutation occurs at a CpG dinucleotide and alters the primary base of the 
codon to a T (CGA>TGA) forming a termination signal.
10 of the missense mutations affected bases potentially involved in splicing. These 
included five substitutions altering splice acceptors and one altering a splice donor. In
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addition we found 2 intronic deletions, which directly alter invariant splice site 
dinucleotides. 2991-4 del ATA changes the intron 17 acceptor site AG>TG, whilst 
6641+1 del G appears to shift the intron 35 donor site 1 bp upstream. Three other 
potentially significant intronic sequence variations were found; 3113+3 ins A, 4111-8 del 
GTT and 288+5 G>C. None of these has been previously reported
A second class of mutations, frameshifts, were detected in 18 patients. 14 were small 
deletions ranging from 1 bp to 23 bp in length. In this group only 499 del TGTT and 
1756 del ACTA have been previously reported by other investigators. However, four 
others deletions had closely related mutations described in the literature, such as 3758 to 
3762 del TCTAC related to 3759 to 3763 del CTACC was reported by (Ars et al., 2000). 
All deletions were entirely exonic except 1-14 to 7 del 21 bp which deletes 14 bp of non­
coding sequence upstream of exon 1 together with 7 bp of exon 1 thereby removing the 
start codon.
Together, frameshift and nonsense mutations that would be expected to truncate the 
reading frame constituted 39 of the 82 mutations detected (497.6%) in patients who 
fulfilled the NIH criteria. The distribution of these mutations appears to be evenly spread 
within the gene, with 27/44 (61%) predicted to terminate the protein in or upstream of the 
GRD.
A third class of mutations, insertions and deletions, were detected in 11 patients. Seven 
insertions were detected comprising five 1 bp insertions and two 2 bp insertions. None of
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these insertions has been previously described. Deletions detected included four in-frame 
deletions; two removing a single amino acid and two removing two consecutive amino 
acids. Only 2970 del AAT AM991 and 7096 del 6 ANF2366-7 have been previously 
reported.
Four different conservative base substitutions were found in five unrelated, definitely 
affected patients. No other variations were detected in any of these patients and none of 
these conservative base substitutions were found in 260 normal chromosomes. Sequence 
variations 2040 C>T C680C and 5427 C>T R1808R were found in two patients in whom 
no other family members were available for testing at the time of writing. Another 
patient was found to have 5172 G>A K1724K and, on testing this patients parents, the 
affected mother was found to carry the same variation while the father was found to be 
normal at this position. Finally, the variation 846 G>A Q282Q was found in two 
unrelated patients of eastern descent.
5.1.3 Recurrent mutations.
Twenty of the 77 novel variations were detected in more than one unrelated individual or 
have been previously reported by other investigators. A total of 8 variants were observed 
more than once in this study. All of these variations were single base pair substitutions 
and seven of them occurred at hypermutable CpG dinucleotides. In this study 6 sequence 
variations were each found in two unrelated cases; 1885 G>A G629R, 4537 C>T 
R1513X, 6709 C>T R2237X, 3826C>G R1276G, and 3827 G>A R1276Q. Base 6792
106
was mutated differently in two different patients, C>A and C>G both of which give 
Y2264X. Two sequence variations were detected in three unrelated patients; the nonsense 
mutation 1318 C>T R440X has been previously reported while the missense variation 
1466 A>G Y489C is novel.
Two pairs of mutations were found to be very closely related, affecting a different base in 
the same codon. Codon 844 was alternatively mutated CTT>TTT (L844F), and 
CTT>CCT (L844P). The latter sequence change was found once on its own and also in 
combination with another missense change, 2514 C>G 1838M. It is unclear whether these 
occurred in cis or trans and which is the pathogenic mutation. As the L844P change was 
also found alone in a definitely affected patient and is one of at least four known 
variations of this codon, it is suspected that this change is the causative mutation, 
although more work to clarify this will be needed. Neither 3826C>G R1276G, 3827 G>A 
R1276Q have been previously described and both were found in two unrelated cases in 
this study. However two other mutations of this codon, 3826 C>T R1276X, 3827 G>C 
R1276Q have been previously reported (Heim et al., 1995). Twenty other mutations 
found in this study were also found to have closely related mutations in the literature. Of 
particular note is 1466 A>G Y489C, which was found in 3 cases in this study but has not 
been previously reported although (Fahsold et al., 2000) reported an identical mutation of 
an identical codon 2 downstream of Y489C (1472 A>G Y491C).
The positions of all the mutations seen are shown on a histogram- Figure 15. Although 
there seems to be a general spread of mutations found throughout the gene, we found no
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sequence changes in exons 1, 5, 9a,15, 20, 23a, 27b, 29, 30, 34, 35, 43, 44, 45, 47, 48, 
48a and 49.
While I find that mutations are evenly distributed along the NF1 coding region, the scale 
of the study allows further analysis of possible mutation hotspots and possible functional 
domains. 22% of mutations fall within the GAP-related domain, but when the mutations 
are analysed by type and a weighted distribution calculated for each exon, a number of 
missense and single amino acid mutations were found to be clustered in the region; exons 
11-17. This therefore confirms the findings of (Fahsold et al., 2000) that this represents 
an important area of the protein. Figure 11 shows the weighted distribution of missense 
mutations and single base changes in the NF1 gene. The relative mutation frequency was 
calculated by dividing the number of missense or single base changes by the base pairs 
per exon. The value is then shown as a ratio between the exon-specific mutation densities 
and the average mutation density for the whole gene (28/8457bp). A clustering can be 
seen between exons 10-17.
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Figure 15. Histogram showing site of mutations found in NF1
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Figure 16 W eighted distribution of missense mutations and single base changes in the NF1 gene. The 
relative mutation frequency was calculated the dividing the number of missense or single base 
changes by the base pairs per exon. The value is then shown as a ratio between the exon-specific 
mutation densities and the average mutation density for the whole gene (30/8473bp). A clustering can 
be seen between exons 10-17. Between exon group and number of mutations present x 2 =20.85, d f 3, 
p=0.0001. Mutation rate is greatest between exons 1-20: x2 =H -74, df 2, p=<0.005, compared to 
exons 21-49: x 2 =9.1, d f 2, p=<0.01. The pink boxes represent cAMP/PKA domain and the GRD.
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5.1.4 Polymorphisms
A total of 19 sequence variations were found either in a normal subject or in an affected 
patient who already had a mutation characterised- Table 5. Of these 14 had a rare allele 
frequency of less than 0.05 and eight were only found in a single subject in the entire 
study (167 subjects). Seven of the polymorphisms found were in coding sequence and 
the remaining 12 all fell within 40 bases of an exon. All but three of the polymorphisms 
were single base pair substitutions, six being transversions and 10 being transitions of 
which four occurred at CpG dinucleotides. The remaining three polymorphisms 
comprised two deletions involving a single T and one deletion of 5 bp.
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' Found with
Exon Base P Q Aa Change P q Unaff Definite Oth
ers
1 1-22 G>C G C 0.984 0.016 Y 7486 C>T R2496X Y
2 61-4 del T 9T 8T 0.996 0.004 1642-2 A>G
2 168 C>T C T S56S 0.959 0.041 Y 4045 ins TS1373X Y
4 b 528 T>A T A D176E 0.996 0.004 Y
5 702 A>G A
.
G L234L 0.728 0.364 y many Y .!
7 889-31 del ATT AT 0.996 0.004 1885 G>A G629R
10 b 1393-32 C>T C T 0.707 0.403 Y many Y
10 c 1528-29 del T 8T 7T 0.694 0.320 v many y
11 1642-25 T>C T C 0.973 0.027 Y 7096 del 6 Y
12 a 1810 T>C T C L604L 0.993 0.007 4255 A>G K1419E
16 2617 C>T C T R873C 0.996 0.004 1-14 to 7 del 21 bp
17 2851-16 T>C T C 0.977 0.023 Y 3528 del AL1183X
22 3867C>T C T F1289F 0.996 0.004 1885 G>A G629R
29 5546-19 T>A T A 0.598 0.471 y many
32 6084+8 C>G C G 0.996 0.004 1318 C>T R440X
33 6173 C>A c A A2058D 0.995 0.005 6181del 8bp 
D2074X
'.39 ■ ■; 7126+37 G>C G C 0.937: 0.063 Y many Y 1
42 7395-29 A>G A G 0.666 0.356 Y many Y j
46 8050+20 G>A G A 0.989 0.011 Y
Table 5: Polymorphisms
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Part 2: Mutation screening in Noonan-Neurofibromatosis syndrome (NFNS)
5.2 Noonan-Neurofibromatosis syndrome (NFNS)
Six cases of NFNS were studied. In all cases the presence or otherwise of NF1 features, 
complying with the NIH NF1 diagnostic criteria were documented. They were also 
examined specifically for features of Noonan syndrome with the criteria used by Colley 
et al (Colley et a l , 1996) in their clinical study either by myself or Dr Elmslie from GOS. 
These were Noonan facial appearance with hypertelorism; downslanting palpebral 
fissures; ptosis; malar hypoplasia and epicanthic folds; low posterior hair line; low-set 
posteriorly rotated ears; short, broad and/or webbed neck; pectus abnormality; cubitus 
valgus; short stature; cryptorchidism/genital anomaly and cardiac defect. The clinical 
features of all six cases are summarised in Table 6. Clinical photographs of cases 1, 3, 4 
and 6 are shown in Figure 17.
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Table 6
Case 1 2 3 4 5 6
NF1 Features
• >6 CAL macules ✓ s ✓ ✓ ✓ ✓
• >2 neurofibromas S
• plexiform neurofibromas
• axillary/inguinal freckling S s ✓
• >2 lisch nodules V X X X X
• osseou s lesion
• Family history V ✓
Noonan syndrom e features
• hypertelorism ✓
• downslanting palpebral fissures V ✓
• ptosis s s ✓ ✓ ✓ ✓
• malar hypoplasia ✓
• epicanthic folds ✓
• low posterior hairline ✓
• low set posteriorly rotated ears ✓ V ✓
• short/broad/webbed neck ✓ ✓ S
• pectus abnormality ✓
• cubitus valgus
• short stature s
• cryptorchidism/genital abnormality
• cardiac defect X X ✓ X
All cases except case 5 fulfilled NF1 diagnostic criteria and also had Noonan facies with one or other 
features of Noonan syndrome. The cardiac defects seen were atrial septal defect, coarctation of aorta 
and pulmonary stenosis. Four cases had feeding problems in the neonatal period. Other clinical 
features found were: case 1 also has widely spaced nipples and scoliosis, case 6 has keratosis 
pilaris. Ages of patients: Case 1- 20yrs, Case 2- 18yrs, Case 3- 7yrs, Case 4- 7yrs, Case 5- 6yrs, Case 
6- 9yrs.
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Figure 17 NFNS cases
(a) Case 1
(b) To the left 
Case 3.
(c) Case 4 
below.
(d) Case 6
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Case 1: A 20 year old man with 7 CAL macules, axillary freckling, 10 neurofibromas, 
Lisch nodules, and a scoliosis with a structural cervical vertebral abnormality. He had 
downslanting palpebral fissures, ptosis, a short/broad neck, widely spaced nipples, and an 
atrial septal defect. He was of short stature and needed extra help at mainstream school. 
There was no family history of similar findings.
Case 2: An 18 year-old man with more than six CAL macules and axillary freckling. He 
had severe feeding difficulties as n infant, requiring nasogastric tube feeding for 18 months. 
He had ptosis, low set posteriorly rotated ears, and coarctation of the aorta. Height was on 
the 10th centile. Intellectual development was normal. His father also had ptosis and one 
CAL macule.
Case 3: A 7 year old boy with more than six CAL macules and axillary freckling. He had 
hypertelorism, ptosis, low-set posteriorly rotated ears, and a webbed neck. There was no 
cardiac defect by echocardiography, and intellectual development was normal. There was 
no significant family history.
Case 4: A 7 year-old boy with more than 12 CAL macules. There were no other features of 
NF1, but his father had 6 CAL macules and axillary freckling. He had downslanting 
palpebral fissures, ptosis, low set posteriorly rotated ears and a webbed neck. Intellectual 
development was normal and he had a normal echocardiogram.
Case 5: A 6 year-old boy with more than 6 CAL macules. There were no other features of 
NF1, but his mother had a single, large CAL macule and Lisch nodules, low hairline, and a 
short neck. He did not therefore fulfil the NIH NF1 diagnostic criteria. He had ptosis, 
epicanthic folds, low posterior hairline, and low set ears. On echocardiogram he had 
pulmonary stenosis. As an infant he had had severe feeding problems, which improved at 2
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years o f  age.
Case 6: A 9 year-old boy with more than sic CAL macules and axillary and inguinal 
freckling. He had feeding problems as an infant. He had pectus excavatum, ptosis, malar 
hypoplasia, scoliosis, keratosis pilaris and developmental delay. Echocardiogram and MRI 
of the brain were normal. His mother had one large CAL macule on the right thigh.
I examined the possible mechanism for the relationship between NF1 and NS by 
undertaking mutation analysis of the entire coding region of the NF1 gene in these 6 cases. 
Mutations in the NF1 gene were identified in cases 1 and case 5. Case 1 had a 2-bp 
insertion in exon 23-2,4095 ins TG. Case 5 was found to have an in-frame 3-bp deletion in 
exon 25, 4312 del GAA. In the four remaining cases, heterozygous polymorphisms were 
detected at at least one site within the gene indicating that there was not a whole gene 
deletion. Parental samples were available only for the mothers of cases 1 and 5, these were 
negative for the above mutations.
In collaboration with St Georges Hospital Medical School Clinical Genetics Department, 
and Professor M. Patton and Dr K. Kalidas, the four cases that were not found to have a 
mutation in the NF1 gene were screened for sequence variations in the Noonan syndrome 
PTPN11 gene. Unfortunately, no more DNA was available on cases 1 and 5. No mutations 
of the PTPN11 gene were identified on samples 2, 3,4 and 6.
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Part 3: Effect of different mutations in NF1 on splicing efficiency.
5.3 The functional minigene splicing assay
The sequence variations generated by the first part of this project were studied and a 
number were chosen for further analysis using the minigene system. They were chosen 
because they were either a known mutation that affects splicing, a sequence variation where 
the mode of causing disease was unclear, or where there was a clinical need to know if this 
was a disease causing mutation. The assay is described in methods section 4.4 and figure 
15.
5.4 NF1 intronic mutation exon 3+5 G>C
The sequence variation, exon 3+5 G>C was found in a three generation family that had 
been tested for NF1 gene mutations using CSA in Part 1 of this project. The significance of 
this intronic mutation and whether this was the disease causing mutation was unclear. The 
index case, at age 82, has classical features of NF1 including multiple cafe-au-lait macules, 
neurofibromas and axillary and inguinal freckling. Her son was similarly affected and died 
in a road traffic accident. Her granddaughter additionally had macrocephaly and died aged 
31 from a malignant nerve sheath tumour affecting the coeliac axis.
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5.4.1 The intronic mutation 3+5 G>C is a splicing mutation
Amplification of exon 3 in mutant and WT DNA and cloning into pUC19 is decribed in 
methods section 4.5 and Figure 13. The functional splicing assay is a technique, as 
outlined in methods section 4.4, that involves the insertion of exon/exons into a minigene 
system, in this case PTB (a-globin-fibronectin EDB illustrated in the introduction) giving 
rise to a hybrid minigene. This will allow the inclusion or exclusion of the exon in the 
transcript to be assessed.
Figure 18A, shows the PCR product after exon 3 amplification. Figure 18B is a 
schematic representation of the amplicon incorporating exon 3 and flanking intronic 
sequences and how this fits in the PTB minigene.
118
lkb A
1018bp
516bp -
B NF1
V 3 0 9bp 8 4 b p
IVS 2 e x o n  3
4 6 2 b p
IVS 3
Exon 3 WT TCTTGCTGGG/gtaagtaaa 
Exon 3 +5G>C TCTTGCTGGG/gtaactaaa
- 4 - 3 - 2 - 1  + 1 + 2 + 3 + 4+5
Figure 18 (A) Exon 3 amplification on 0.8% agarose gel. The product is 855bp long. 
(B) Schematic representation of amplicon: exon 3 (84bp) plus 309bp and 462bp of 
flanking intronic sequence at the 5’ and 3’ ends respectively.
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5.4.2 The intronic mutation 3+5 G>C excludes exon 3 from the mature transcript by 
failure of the snRNP U1 to recognise the 5* splice site.
One of the first events in the establishment of a splicing complex in eukaryotic exons is 
the binding of snRNP U1 (Burge et al., 1998; Stark et al., 2001) to AGGTRAGT 
sequence (Zhang and Rosbash, 1999) at the 5'SS. Therefore in the case of G>C 
substitution in this exon 3 case, the complementarity for snRNP may be affected. This in 
turn would affect the recognition of the 5'SS by the splicing complex and produce an 
alternative splicing pattern excluding exon 3.
However there is some variability in the 5’SS sequence recognised by the snRNP Ul. 
This can be seen in exons 7 and 37 of NF1. In the former a cytidine in exactly the same 
position as in the exon 3 mutant is seen and in the latter a thymidine is seen at exactly the 
same position as in the exon 3 mutant. However in both these cases the exon is 
constitutively incorporated in the mature transcript.
• Exon 3 wild-type -CTTGCTGGGgtaagtaaat-
• Exon 3 G>C - CTTGCTGGGgtaactaaat-
• Exon 7 wild-type -CTTGCTGGGgtaactaaat-
• Exon 3 7 wild-type - CTT GCT GGGgtaattaaat-
To test the hypothesis that the defective splicing pattern seen in exon 3 is due to reduced 
affinity for the 5’SS by snRNP Ul a Ul complimentary to the G>C mutation was 
constructed (Ul C>G), using oligo snRNP Ul, that should have the same affinity for the 
5'SS as in the wild-type sequence and factor, -Figure 19.
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Figure 19 (A) RNA products generated by the splicing assay. Two products are seen 
on agarose gel electrophoresis, with the 239 band representing an RNA product 
lacking exon 3 and the 323bp band product including exon 3, as indicated 
schematically on the right of the gel. Note the C>G minigene excludes exon 3, while 
the WT gene includes this exon. Splicing is rescued (that is, exon 3 is included) by 
the G>C/C>G-U1) but not by expression of the WT-Ul snRNA (exon 3 G>C/WT- 
Ul). (B) Normal base pairing between the 3’end of exon 3 and WT-Ul snRNA. 
indicates wobble association. The nucleotide change observed in the patient (G>C 
at the +5 position) reduces base pairing between the RNA and the Ul snRNA as 
shown. (C) The variant snRNA (C>G-U1) changed to complement the nucleotide 
change seen in the family; note the restoration of appropriate base pairing
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The altered Ul was co-transfected with NF1 exon wild-type and NF1 exon G>C and the 
splicing products analysed by RT-PCR using the same oligonucleotides as before. The 
results are seen on the gel in Figure 19. It can be seen that the G>C mutation is 
recognised by the modified complimentary Ul where a band of 323bps now appears, 
indicating that the modified Ul has attached to the 5'SS and rescued the splicing defect 
caused by the G>C change in Exon 3 (Lane NF 1/Exon 3 G>C/U1 C>G). The identity of 
this band was confirmed by sequencing. This result also shows that in the case of exon 3 
complete complementarity with Ul is needed for inclusion of this exon.
5.43 Involvement of a context-specific hnRNP HI binding site hampering its 
interaction with Ul snRNA.
Considering the great complexity of interactions between snRNPs and pre-mRNA, the 
question remains as to whether the +5G>C substitution simply abolishes Ul binding to 
pre mRNA or do other 5'SS recognition mechanisms also play a role? Indeed why is 
complete complementarity not needed for Ul binding in the cases of exons 7 and 37 in 
the same gene? Therefore further studies on the snRNP Ul and 5'SS interactions were 
undertaken by pull-down analysis using RNA extracted from cells with mutant and wild- 
type exon 3. This work was performed by Dr. E. Burratti, ICGEB, Italy (Buratti et al 
2004).
The first steps of splicesome assembly at the 5' SS can be studied by pull-down analysis 
where bands representing the different proteins associated with the pre-mRNA are
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visualised. To maximise the efficiency of the pull-down analysis 21 nucleotides upstream 
and 34 nucleotides downstream of the GT consensus sequence of exon 3 were included in 
the RNA samples. These non-conserved intronic sequences flanking the 5'SS have been 
previously shown to influence the binding of snRNP U1 (Puig et al., 1999). The results of 
this study are shown in Figure 20. In the exon 3/wild-type lane 4 bands are seen 
approximately 70Kda, 32.5Kda and two at 25Kda that disappear in the exon 3 mutant (+5 
G>C) lane. To determine the identity of these proteins they were sequenced by the 
Proteomic facility at the ICGEB and compared to proteins present in the 
HumanGenBankDatabase.
As seen in the figure the proteins were identified as: U1-70K and Ul-A, which are 
components of snRNP Ul, and snRNP B/Bl that is a common component of all snRNP 
U (Stark et al., 2001). Other components of snRNP U: Ul-C, E, F, G, D1-D3 were not 
seen probably because of their low molecular weight (17.5Kda- 8.5 Kda). This result 
confirms the hypothesis that the +5 G>C mutation inhibits snRNP U1 binding at the 5'SS 
and thus causes skipping of exon 3.
As mentioned previously, some variability exists in the sequences recognised by snRNP 
at the 5’SS, as seen in exons 7 and 37 of NF1. See sequences below, the blue bases are 
those that base-pair with snRNP U1.
SnRNP U1:  gguccauucaua
Exon 3 wild-type: CUUGCUGGGguaaguaaa
Exon 3 G>C: CUUGCUGGGguaacuaaa
Exon 7 wild-type: GAUCUUAAGguaacaugcu
Exon 37 wild-type: CUUAAUAAGguaauuacug
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1 P/Q Splicing Factor
2 KSRP
3 U1-70K
4 p54nrb
5 hnRNPHl/H'
6 hnRNPD-like 
7U1-A
8 Ul-B/Bl
(wt) (G>C) (wt) (wt)
Ex3 Ex3 Ex3 
B (wt) (G>A) (G>A,G>C)
X
Q-Z
QCc-C
►
Figure 20 (A) To gain insight into why NF1 +5 G>C exon 3 is skipped while exons 
1,7 and 37 are constitutively included the protein complexes binding in 
correspondence to the exon/intron boundaries were analysed by RNA pull down 
analyses and mass spec identification of the bands. It can be seen that the +5G>C 
mutation causes the loss of the binding of U1 related proteins. Furthermore we 
observe the presence of hnRNP H l/H  (previously shown to play key roles in the 
splicing process both as a component of splicing enhancers or silencers) in both WT 
and mutant exon 3 but not in the other exon/intron boundaries. (B)A binding motif for 
hnRNP Hl/H' (GGGG) was observed in exon 3 5’ss. The introduction of a -2G>A 
substitution destroyed this run both in the wt and mutant minigenes. These two 
constructs: exon 3 (G>A) and exon 3 (G>A, G>C) were then analysed. Pull down 
analysis shows the disappearance of a 57kDa protein band, identified as hnRNP 
Hl/H'
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In the case of exon 7, a similar C is present at +5, and in exon 37 a T is present at +5, 
these situations are analogous to the G>C base change seen in the exon 3 mutant. 
However they do not affect exon skipping. So why does the G>C change so dramatically 
affect recognition of exon 3 by snRNP Ul?
In the adjacent 5' exonic sequence a G motif can be seen in positions -3, -2, -1 and 1. 
From the literature it is know that this motif is necessary for the binding of hnRNPH. 
This allows us to suggest a new model of splicing for exon 3: if hnRNP H binds to the 
GGGG sequence near the 5'SS, the bases then available for the interaction needed with 
snRNP Ul at the exon 3 splice site are reduced in number. If in addition there is a 
sequence change of G>C, the number of bases available to pair with diminish even 
further. Also this mutation is right in the middle of the region and splits the remaining 
binding region into two sections. The combination of these events could therefore be 
what prevents snRNP Ul interaction and thus exclusion of exon 3.
To study this model further, the putative hnRNP H binding motif was removed by site 
directed mutagenesis (see materials and methods), to see if correct splicing could be 
achieved. In the exon 3 wild-type and G>C mutant a -2G>A sequence change was 
introduced, to make a double mutant: NFl/exon 3 G>C, G>A. An NFl/exon 3 wild-type, 
G>A was also constructed. As described previously this was subcloned into the PTB 
minigene and transfected into Hela cells. At RT-PCR analysis- Figure 21. It can be seen 
that whilst the -2G>A mutation has no effect on inclusion of exon 3 in the wild-type 
mature transcript, it does rescue the splicing defect that had been seen in +5 G>C mutant 
confirming the hypothesis.
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Figure 21. -2G>A mutation successfully completely rescues the +5G>C mutation.
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A further pull-down analysis was then performed to verify at molecular level the 
interaction of snRNP Ul with this new set of mutants and to see if hnRNP H was also 
involved. In Figure 21 it can be seen that a 57Kda band disappears in the lanes where 
the -2G>A mutation has been introduced. On sequencing this band after mass 
spectrometry it was identified as hnRNP Hl/H'. This is in keeping with the theory that the 
-2G>A change prevents binding of hnRNP Hl/H' by changing the sequence from gggGT 
to gAgGT.
5.5 NF1 'nonsense' mutation exon 37 C6792G
This sample was obtained from a female patient with classical features of NF1, including 
cafe-au-lait macules, axillary freckling and multiple neurofibromas. Her son is also 
affected. This mutation had been previously reported in the literature and known to affect 
splicing from studies at RNA level (Messiaen et al., 1997).
5.5.1 Mutation exon 37 C6792G causes skipping of this exon in the mature 
transcript.
Amplification of exon 37 mutant and WT and cloning into pUC19 is described full in 
methods section 4.6 and Figure 14. .Exon 37 and 20 bp of flanking intronic sequence 
was originally amplified like exon 3 into the PTB minigene. When transfected this gave 
very poor exon inclusion in both the mutant and wild-type. This indicated that long 
distance sequences surrounding this exon may be important for inclusion of it. So a large
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fragment was cloned into pcDNA3 that is able to allow insertion of longer sequences into 
the plasmid. It is rare, but not unheard of, that long distance sequences are involved in 
recognition of an exon (Romano et al NAR 2001,29;4: 886-894).
After subcloning of the insert (consisting of exons and respective introns 34, 35, 36, 37, 
38) into pcDNA3 the 'functional splicing assay' was performed. The plasmid constructs 
of both wild-type and mutant NFl/exon 37 C6793G were transfected into HeLa cells and 
the splicing products analysed by RT-PCR using the oligonucleotides 'Oligo pcDNA 3' 
sense and antisense. Figure 22A shows a schematic representation of the insert and 22B 
RT-PCR analysis gel. It can be seen that the C>G substitution at position 6792 which 
produces a STOP codon, causes skipping or exclusion of not only exon 37 but also of 
exon 36.
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Figure 22 A) Schematic representation of pcDNA3 with NF1 exons 34-38 as the 
insert. B) RT-PCR analysis on 2% agarose gel. Two products can be seen; a larger 
band in lane 1 which includes exon 37 and a smaller band in lane 2 excluding exon 
37. Therefore the C>G substitution causes skipping of exon 37. The results also 
show that as hypothesized, even a translationaly silent mutation in nucleotide 6792 
(C6792T) causes skipping. This observation indicates that the nucleotide change 
itself rather than the creation of a stop codon produces the aberrant splicing. It can 
also be seen that the cis-acting element affected by the nucleotide change at position 
6792 is also necessary for the correct splicing of exon 36. C) Schematic diagram of 
the process of aberrant splicing in the presence of C6792G mutation.
5.5.2 The 'same sense' C6792T mutation also causes skipping of exon 37
Various theories have been suggested to explain exon skipping in the presence of a PTC, 
STOP codon. One is that the STOP codon is read and that this causes exon exclusion. 
Another is that, it is not the PTC which is important but instead the specific nucleotide 
change itself which interrupts an essential sequence in that exon that is needed for its own 
inclusion. To assess these hypotheses I created a new mutation at exactly the same 
position, 6792 which is in the middle of exon 37 and 36 bases from the splice site. The 
change was a same sense or 'silent' sequence variation where the C became T (NFl/exon 
37 C6792T). This was done by site-directed mutagenesis using oligonucleotides 'Oligo 
C6792T'. This new amplicon was processed in the same way as the C>G substitution by 
first cloning into the Sma I site of pUC19, sequencing to confirm the single base change, 
cut out and subcloned into the BamHI/Xho I site of pcDNA3, transfected in HeLA cells, 
RNA extracted and RT-PCR analysis performed. As can be seen in Figure 22 the 
sequence change C6792T causes skipping of exon 37 confirming the hypothesis that it is 
the nucleotide itself which is important.
5.5.3 Skipping of exon 37 is caused by interruption of an exonic splice enhancer?
From previous studies and the results found in the C6792T mutation, other mutations that 
may interrupt an ESE sequence in exon 37 were identified and analysed. The single 
nucleotide changes at a specific position could be altering the sequence of an ESE and 
thus its function. Indeed an ACAAC motif is seen to be conserved in all cases where
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correct splicing occurs. Studies of the secondary structure of RNA in regions with this 
sequence show reduction of free energy (Turner and Sugimoto, 1988; Zuker and Stiegler, 
1981), and a loop motif accessible to splicing factors- Figure 23
Therefore this is a putative ESE sequence. ESE's are known to occur in constitutive and 
alternative exons and are a necessary requirement for the inclusion of that exon (Cooper 
and Mattox, 1997; Gersappe and Pintel, 1999; Shiga et al., 1997; Vuillaumier-Barrot et 
al., 1999; Watakabe et ah, 1993). To verify whether in the case of exon 37 this particular 
region does indeed represent an ESE site or not, further studies using site directed 
mutagenesis were undertaken. Single point mutations were introduced by PCR using 
specific oligonucleotides. The mutations created are shown in listed below:
• A6791T oligonucleotides used: Oligo A679IT
• A6793T oligonucleotides used: Oligo A6793T
• A6794T oligonucleotides used: Oligo A6794T
• C6795G oligonucleotides used: Oligo C6795G
The DNA fragment studied in all cases is 3280 base pairs long. Sequencing of this to 
check for the absence of mutations that may have been introduced by the Taq polymerase 
reaction would be laborious. However the use of two restriction enzyme sites; EcoRI 
(position 1259) and Afe I (position 1642), respectively upstream and downstream of exon 
37 allow a reduction in the number of base pairs in the DNA fragment to be sequenced 
(386 bp).
The new amplicons were processed as described in previous sections and analysed after 
RT-PCR analysis. The results can be seen in Figure 24. In mutations A6791T, A6793T, 
A6794T normal splicing was observed. Mutations C6795G showed the triple band
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Figure 23 Diagram of the secondary structure of RNA which incorporates the ESE 
sequence hypothesis and the corresponding free energy reduction.The red bases 
represent the conserved sequence of the exposed loop of RNA in which correct 
splicing occurs.
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Position 6792
t_________
GTTdCTTAAAAGGACCTGACACTTACAACAGTCAAGTTCTGATAGAAGCTACAGTAATAkCACTAA...
TTA AAA GGA CCT GAC ACT T|AC AAC| AGT CAA GTT CTG ATA GAA GCT ACA GTA ATA wild-type 
leu lys gly pro asp thr tyr asn ser gin val leu ile glu ala thr val ile
ESE?
TTA AAA GGA CCT GAC ACT TfTC AAC| AGT CAA GTT CTG ATA GAA GCT ACA GTA ATA A6791T 
leu lys gly pro asp thr phe asn ser gin val leu ile glu ala thr val ile
TTA AAA GGA CCT GAC ACT TlA C IA d  AGT CAA GTT CTG ATA GAA GCT ACA GTA ATA A6793T 
leu lys gly pro asp thr ty r  ser gin val leu ile glu ala thr val ile
TTA AAA GGA CCT GAC ACT T|AC AIC |AGT CAA GTT CTG ATA GAA GCT ACA GTA ATA A6794T 
leu lys gly pro asp thr ty r  ile ser gin val leu ile glu ala thr val ile
TTA AAA GGA CCT GAC ACT TjAC AAG |AGT CAA GTT CTG ATA GAA GCT ACA GTA ATA C6795G
leu lys gly pro asp thr ty r  lys ser gin val leu ile glu ala thr val ile
A6791T A6793T A6794T C6795G
Figure 24 In mutations A6791T, A6793T, A6794T normal splicing was observed. 
Mutations C6795G showed a triple band pattern for splicing.
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pattern for splicing confirming that the ACAAC region is necessary for splicing 
regulation. For a fuller picture extensive site-directed mutagenesis was undertaken of all 
the bases between positions 6788 and 6799 with all three possible substitutions. Figure 
25 show these results. Mutations at positions 6790, 6791, 6793, 6794, 6796, 6797 do not 
influence splicing, so that exons 34-38 are correctly included. Any mutation at positions 
6792 and 6795 lead to aberrant splicing. A three band profile is seen for all of these, 
where the upper band represents correct assembly of the 5 exons, the intermediate band is 
composed of exons 34, 35, 36 and 38 with missing exon 37. The lower band consists of 
exons 34, 35, and 38, in this case both exons 36 and 37 have been skipped. Positions 
6789 and 6798 are interesting (both have T here in the WT). If the T is substituted with 
either C or G normal splicing is observed, whereas if it is substituted with its 
complementary base, an A, exon 36 skipping (confirmed by sequencing) is seen. 
Therefore a new, complicated, regulatory element, that does not function through the 
binding of a SR protein and that is capable of influencing correct exon inclusion is 
demonstrated.
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C6788 T6789 T6790 A6791 C6792
A G T A C G A C G C G T A G T W T C -
NFl/exon 37 NFl/exon 37 NFl/exon 37 NFl/exon 37 NFl/exon 37
A6793 A6794 C6795 A6796 T6797
C G T C G T A G T C G T A C G C -
NFl/exon 37 NFl/exon 37 
T6798 C6799
A C  G A G T C-
Figure 25 Minigene analysis on 2%  agarose gel of all possible mutations between 
bases 6788 and 6799. As can be seen, any mutation at position 6792 and 6795 and 
C6799T generates a splice 3 band pattern with exon 37 skipping (intermediate 
band) and skipping of both exons 36 and 37 (lower band). A>T substitution at 
positions 6798 and 6789 skips only exon 36. All other mutations do not alter 
splicing as can be seen by the single band on the gel of exactly the same size as 
the WT sequence.
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5.6 NF1 silent mutation exon 28 5172 G>A
This sample was obtained from a large family with many NF1 affected members. The 
female proband has classical features of NF1 including cafe-au-lait macules, axillary 
freckling and multiple neurofibomas, in particular spinal neurofibromas which 
necessitated surgery. She has four children, three of whom also have the disorder and 
additional features including learning difficulties and scoliosis. The entire NF1 gene was 
sequenced as described in materials and methods and only a same sense or silent 
sequence variation was found: exon 28 G5172A (leu-leu). A whole gene deletion was 
excluded by the checking for the presence of known polymorphisms.
5.6.1 Exon 28 G5172A does not cause skipping of the exon.
Exon 28 with some flanking intronic region was amplified using oligonucleotides exon 
28/Nde and processed through the splicing assay as previously described in section 4.2 
using initial subcloning into pUC19 and then the PTB minigene system. Exon 28 wild- 
type and mutant G>A constructs were obtained and checked by sequencing. After 
transfection, RNA extraction and RT-PCR analysis, it was found that this sequence 
variation does not affect splicing of exon 28, see Figure 26.
This case provides a negative control for this assay, and demonstrates its potential 
usefulness as a diagnostic splicing assay particularly in the case of assessment of 
sequence variations found in the high-throughput sequencing of large genes.
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2 log ladder WT Exon 28 G>A
Figure 26. Both WT and exon 28 G>A sequence variation show bands of size 
431. Exon 28 is included in both cases, therefore there is no aberrant splicing.
1 kb Ladder WT Exon 6 G>A
Figure 27 Both WT and exon 6 846 G>A sequence variation show bands of size 
398bp which includes the exon. Therefore there is no aberrant splicing.
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5.7 NF1 silent mutation exon 6 846 G>A in a family with familial Primitive 
Neuroectodermal tumours (PNETs) and cafe-au-lait patches.
These samples were obtained from two sisters who had had supratentorial primitive 
neuroectodermal tumours (PNETs) diagnosed in childhood, the elder sister subsequently 
died. PNETs are a highly lethal paediatric malignancy that is usually sporadic and of 
unknown aetiology. PNETs are not a common brain tumour found in NF1 although case 
reports do exist in the literature (Scheurlen and Senf, 1995; Thiel et al., 1995). On 
examination both girls were found to have numerous cafe-au-lait patches and axillary 
freckling, such as that seen in neurofibromatosis type 1. They were bom from Pakistani 
consanguineous (first cousin) parents who were not clinically examined for features of 
NF1 but who claimed to be unaffected. They have a younger brother who at the age of 5 
years also has multiple cafe-au-lait patches.
After sequencing the entire coding region of the NF1 gene by CSA a single base change 
was found in exon 6 in both affected sisters, G846A. This was a same sense, or silent 
change that did not affect the amino acid, Gln-Gln.
5.7.1 Exon 6 846 G>A sequence variation does not cause skipping of this exon.
Exon 6 with some flanking intronic region was amplified using oligonucleotides exon 
6/Nde and processed through the splicing assay as previously described in section 4.2 
using the PTB minigene system. Exon 6. wild-type and mutant G>A constructs were
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obtained and checked by sequencing. After transfection, RNA extraction and RT-PCR 
analysis it was found that this sequence variation does not affect splicing, see Figure 27.
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5.7.2 PMS2 gene mutation as a possible cause of an NFl-like phenotype with a 
highly malignant phenotype and high recurrence risk.
There are at least two reports of PNET in NF1. One of these tumours was peripheral 
developing in a pre-existing plexiform neurofibroma (Chan et al 1996) The other was a 
large sPNET that developed after chemo- and radiotherapy for a brain stem astrocytoma 
(Raffel et al 1989 Neurosurgery 25:959-964).
A similar sibship to the one described in this thesis was subsequently reported at the 
European Society of Human Genetics conference 2003 (De Vos et al, St James 
University Hospital, Leeds). This family consisted of three siblings with brain tumours in 
childhood from consanguineous parents. The eldest child died from cerebral high grade 
small-round-cell non-Hodgkin lymphoma, the other two had sPNETs. All three children 
had multiple CAL macules but did not fulfil NF1 NIH diagnostic criteria. In this family 
whole genome autozygosity mapping had been undertaken and linkage found to 7p22 
including the PMS2 gene. Subsequently a novel homozygous nonsense mutation in PMS2 
exon 14 was found (De Vos et al 2004 Am J Hum Genet 74:954-964). PMS2 is one of the 
mammalian genes similar to the mutL DNA mismatch-repair (MMR) gene of Escherichia 
coli (Marti et al 2002 J Cell Physiol 191:28-41). The hMutLa heterodimer of PMS2 with 
MLH1 (another mutL homologue) is the major species providing mutL-like MMR 
activity in human cells (Li and Modrich 1995 PNAS 92:1950-1954). Although MLH1 
mutations are the most common cause of hereditary non-polyposis colon cancer 
(HNPCC) (Peltomaki 2001 Hum Mol Genet 10:735-740) PMS2 mutations are, in 
contrast, very rare, having been reported in only five families with cancer (Horii et al,
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1994; Nicolaides et al, 1995)(De Rosa et al 2000 Oncogene 19:1719-1723, Trimbath et 
al 2001 Fam Cancer 1:101-105). In addition review of PMS2 mutations suggests that 
they behave as recessive traits, with little or no evidence of cancer predisposition in 
heterozygotes. This mutation finding significantly widens the spectrum of disorders 
associated with mismatch repair gene defects, and suggests a new form of recessive 
cancer syndrome.
CALs and early-onset neoplasia in combination has also been reported, in particular with 
mutations in MLH1 (Ricciardone et al 1999 Cancer Res 59:290-293).
Subsequently the samples from our family were sent to Leeds and analysed. A PMS2 
gene exon 6 codon 181 homozygous mutation tyr-stop, was found in both the sisters, 
confirming this as the cause of the signs and symptoms of PNETs with a 
Neurofibromatosis-like phenotype in this family.
141
DISCUSSION
Part 1: Mutation screening o f  the NF1 gene
6.1 Automated comparative sequence analysis identifies mutations in 89% of NF1 
patients and confirms a mutation cluster in exons 11-17 distinct from the GAP 
related domain.
In this study direct sequencing and automated CSA was used to study 167 subjects 
including 91 unrelated definitely affected NF1 patients. Putative mutations were found in 
81 of these affected patients (82%) achieving the highest recorded mutation detection rate 
using a single technique for this gene. Given that the current estimate of whole gene 
deletions in this disorder is approximately 10%, this technique may therefore pick up all 
the remaining classes of mutations and potentially replaces all existing technologies, used 
either alone or together, with advantages of increased specificity and sensitivity 
associated with decreased cost and considerably reduced analysis times. A class of 
mutations that would not be detected with this assay are large gene deletions as the test is 
not dosage sensitive. We plan to set up an MLPA (multiplex ligation dependent probe 
amplification) assay to look for whole exon and whole gene deletions in the patients in 
whom we have not found pathogenic mutations by sequence analysis.
Many new mutations have been identified in our study, with 74% being novel. This
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confirms that there are few recurrent mutations in NFL While I find that mutations are 
evenly distributed along the NF1 coding region, the scale of this study allows further 
analysis of possible mutation hotspots and functional domains. The RasGAP activity of 
the central GAP-related domain (GRD) and the structure of the GRD from neurofibromin 
have already been well characterised (Izawa et al., 1996; Upadhyaya, 1998). Indeed 
clustering of mutations has been reported in this region, and much attention has since been 
concentrated on this area. The GRD is not shown to be a significant mutation hotspot in 
this study, with only 22% of mutations falling within this region. A second possible 
functional domain upstream of GRD has also been reported around exons 11-17 (Fahsold 
et al., 2000). When our mutations were analysed by type and a weighted distribution 
calculated for each exon, a number of missense and single amino acid deletions were 
found to be clustered in this region as assessed visually and shown in Figure 11 
confirming that this represents an important area of the NF1 protein.
A similar cluster, which was termed a hotspot, was seen in the study of (Fahsold et al., 
2000) although I detected more mutations in upstream exons. This region is known to be a 
cysteine/ serine-rich domain (CSRD) defined by (Izawa et al., 1996). It has three cysteine 
pairs suggestive of ATP binding as well as three potential cAMP-dependent protein kinase 
(PKA) recognition sites, that are subject to phosphorylation by PKA. As abnormalities of 
cAMP signalling have been demonstrated in Drosophila neurofibromin mutations, it will 
be important to clarify further the link between cAMP and the Ras signalling pathway in 
NF1.
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In addition to clinical utility, the availability of a powerful mutation detection technique 
for the NF1 gene will allow us to address two longstanding questions in NF1. First, do 
phenotype-genotype correlations exist? This could be studied in a large number of patients 
where the whole gene is sequenced and attention paid to the type of mutation and clinical 
sign/symptom. Second, what is the contribution of the NF1 gene to some of the rare 
related disorders, such as segmental NF, gastrointestinal NF, familial spinal NF and 
familial cafe au lait spots. The first example to be studied was the rare syndrome Noonan- 
Neurofibromatosis (NFNS) where patients exhibit features of both disorders.
Part 2: Different mutations in the NF1 gene are associated with 
Neurofibromatosis-Noonan syndrome (NFNS).
The possible mechanisms for the association of Noonan syndrome with NF1 were 
examined by undertaking mutation analysis of the NF1 gene and the PTPN11 gene (found 
in 40% of Noonan syndrome cases) in a cohort of 6 NFNS patients. These mechanisms 
included a) a chance occurrence for the association of Noonan syndrome with NF1, b) 
NFNS as an unusual variant of NS, c) NFNS as an unusual variant of NF1, and d) NFNS 
as a distinct genetic disease.
Two mutations were found in the NF1 gene in this group, and in those without mutations 
whole gene deletions were excluded by confirming the presence of polymorphic sequence 
variations in the gene. In this series Case 1 was found to have a 2bp insertion in exon 23-2 
and case 5 a 3bp in frame deletion in exon 25. These mutations have not been previously 
reported and were not found in testing 100 other NF1 patients (Mattocks et al 2004).
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However, both mutations lie within the GAP-related domain of the gene (exons 20-27a), a 
region previously shown to contain multiple NF1-causing mutations. I did not find the 
previously described 3bp deletion in exon 17 in our NFNS patients. However, I have 
observed this mutation in our series of NF1 patients without NFNS (Results section 3.1 
table 3a), showing definitely that this mutation can cause classical NF1 and is not specific 
for NFNS. Interestingly, case 5 did not fulfill the NIH diagnostic criteria for NF1 and yet 
was found to have a mutation in this gene. This further emphasises the variability of this 
disorder.
A disorder that has similar features and has been found to have mutations in the NF1 gene 
(Wu et al., 1996) and more recently in the PTPN1I gene (Digilio et al., 2002) is 
LEOPARD syndrome (multiple lentigines, electrocardiographic-conduction abnormalities, 
ocular hypertelorism, pulmonary stenosis, abnormal genitalia, retardation of growth, and 
sensorineural deafness). However, the hallmark of this disorder are the lentigines, which 
appear quite different from cafe au lait macules on clinical examination and therefore does 
not appear to be a possible diagnosis in these cases. In four cases of this cohort, mutations 
were not found in either of the two genes; NF1 or PTPN11, suggesting that the disorder is 
a heterogenous group and may be either a separate syndrome or caused by mutations in 
further NS genes still to be elucidated. There is no known association or link with the 
signalling pathways of NF1 and PTPN11 to date.
I conclude that NFNS can therefore, in some, be a subgroup of NF1, and importantly, that 
there does not appear to be a specific NF1 gene change associated with NFNS. The NFNS 
syndrome therefore represents further evidence for the wide genotype/phenotype variation 
seen in NF1 mutations and the likely diagnosis in these cases. While I have found
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mutations in the NF1 gene in some NFNS patients, our results do not exclude the 
possibility that mutations in other genes can also cause NFNS. One potential candidate is 
the PTPN11 gene responsible for many cases of Noonan syndrome. In all four of the cases 
in which I did not find NF1 mutations, we were able to sequence this gene (in 
collaboration), and did not find any mutations. This result would be consistent with a 
hypothesis that most cases of NFNS represent a form of NF1 rather then Noonan 
syndrome. However, the inability with current technology to detect mutations in as many 
as 50% of patients with Noonan syndrome makes it impossible for this hypothesis to be 
tested, as we cannot exclude the possibility that other cases of NFNS will result from 
presently undetectable mutations associated with Noonan syndrome. In the absence of a 
much higher mutation detection rate, this would remain the case even if we were able to 
sequence larger numbers of patients. The important conclusion I was able to draw from 
this work is that NFNS can represent a variant form of NF1 and can be caused by different 
mutations, some of which cause classical NF1 in other individuals. Consequently, these 
results add NFNS to the phenotypic variation associated with mutations in the NF1 gene.
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Part 3: Effect o f  different mutations in NF1 on splicing efficiency.
7.1 The splicing assay, and diagnostic usefulness.
Previous studies examining the effects on splicing of NF1 mutations have analysed RNA 
extracted from individual patients to confirm possible splicing defects. This is, however, 
a laborious technique requiring a potentially difficult RNA extraction from a cell line or 
tissue, and complicated by sources of variability such as, splice site leakiness in some 
tissues and lower levels of expression of mRNA from the mutant alleles. However, in 
many cases the necessary further samples may be hard to obtain or unavailable for the 
laboratory performing the sequence analysis. As an alternative technique utilising 
genomic DNA and circumventing these problems of variability or the need for further 
sampling, I took advantage of a simple minigene splicing assay. In this assay individual 
exons are inserted, along with flanking intronic sequences, into a fibronectin (Fn) 
minigene containing upstream and downstream intronic and exonic sequences sufficient 
to allow splicing. It had been previously shown how this minigene system can be used to 
identify sequences required for the correct regulation of alternative splicing in the cystic 
fibrosis (CFTR) gene (Pagani et al., 2000), and also to identify abnormalities of splicing 
of the ATM gene as a disease mechanism in ataxia-telangectasia (Pagani et al., 2002).
As techniques for the identification of sequence variation become faster and cheaper, 
the distinction between polymorphisms and pathogenic mutations will be an increasing 
challenge. The assay I have used here in the analysis of NF1 families is a potentially 
valuable tool for the identification of those mutations that cause splicing defects. No
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RNA or further samples are required from the patient, making it feasible to carry out 
this further step in the molecular genetic diagnostic laboratory as part of the analysis of 
the DNA sample provided by the referring clinicians. In addition, the minigene system 
effectively recreates within the cell line the splicing defect of each patient, so 
facilitating further studies on the relationship between genotype and phenotype in this 
disease.
7.2 An intronic mutation affects exon 3 splicing with the involvement of a context- 
specific hnRNP HI binding site hampering its interaction with U1 snRNA.
Here genomic DNA comprising exon 3 and flanking intronic sequences from the 
potentially abnormal NF1 gene in this family was amplified and inserted into the 
minigene. Following transfection and expression of the construct in Hep3B cells, the 
mRNA produced by the cells was analysed for splicing pattern by RT-PCR. The exon 3 
+5 G>C mutation dramatically affected pre-mRNA processing, causing exon 3 to be 
completely skipped.
To further confirm the role of this mutation I constructed and expressed in the cells a Ul- 
snRNA complementary to the mutation observed in the patient. One of the early events in 
the process of intron removal from mRNA precursors involves recognition of the 5’ 
splice site by U1 small nuclear ribonucleoprotein (snRNP). This recognition involves 
complementary base pairing, and the substitution of the guanosine by a cytidine in 
position +5 of IVS 3 lessens the degree of U1-snRNA base pairing with the 5’ splice site. 
Altering the complementary cytidine to guanosine in the U1 snRNA was found to restore
normal base pairing, and as predicted co-expression of this altered U1 snRNA with the 
minigene carrying the mutation resulted in rescue of exon 3 splicing. In contrast, 
expression of WT U1 snRNA did not rescue splicing, showing that this does not simply 
result from increased levels of U1 snRNA. This experiment proved that the exon 3 
+5G>C variation is a disease-causing mutation that induces aberrant skipping of exon 3. 
The demonstration of a corrected splicing defect in human NF1 cells opens the way for 
further -omic studies in which corrected cells represent the controls for the NF1 mutation, 
so eliminating the problems of genetic and molecular heterogeneity in different human 
cells and facilitating the identification of critical molecular changes in NFL
Th functional characterisation of the NF1 exon 3 +5G>C mutation was undertaken by Dr 
E. Burratti, ICGEB, Italy to begin to address some unanswered questions: Does +5G>C 
substitution simply abolishes Ul binding to pre mRNA or do other 5’SS recognition 
mechanisms also play a role? Indeed why is complete complementarity not needed for Ul 
binding in the cases of exons 7 and 37 in the same gene? Therefore further studies on the 
snRNP Ul and 5'SS interactions were undertaken by pull-down analysis using RNA 
extracted from cells with mutant and wild-type exon 3. The observation that a Ul snRNA 
complementary to the mutations could rescue NF1 exon 3 skipping (Baralle et al 2003) 
suggests that it is indeed the UlsnRNP-exon 3 5’ ss interaction which is involved. This 
hypothesis was confirmed using pulldown and band shift analyses which demonstrated 
that Ul snRNP was indeed capable of binding to the NF1 exon 3 (wt) donor site and that 
this binding was abolished by the +5G>C mutation. Interestingly, the pulldown analysis 
also showed that the GGGgu donor site sequence of NF1 exon 3 could also bind another
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protein, hnRNP H, which has a well-known ability to affect the splicing process (Caputi 
et al 2002, Chou et al 1999). We have shown using nuclear extracts depleted of hnRNP H 
that binding of this protein to the GGGgu sequence can reduce, but not abolish, Ul 
snRNP binding.
Therefore the sequence of events is as follows; if hnRNP Hl/H' binds to the GGGG motif 
then snRNP Ul does not have enough sequential bases to pair with and therefore the 
splicesome will not assemble and the exon is skipped. If however, as shown by the - 
2G>A mutant, the hnRNP HI/ H' does not bind then snRNP Ul, even in the mutant +5 
G>A can find enough bases to pair with and thus recognise the 5'SS, Figure 28.
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Figure 28. A model that explains these observations through the restricted availability 
of U l snRNA base paring sequences with the 5’ss due to hnRNPH steric hindrance is 
shown. Removal of the GGGG motif (D) results in an extension of the pairing and in 
this context the +5 G>C mutation becomes non pathogenic.
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The binding requirements for hnRNPHl/H’ involve either the presence of GGGX motifs 
and/or consecutive G runs. On analysis of the exon 3 RNA sequences, the most likely 
binding site for this protein is represented by the GGGgu run occurring in correpondance 
with the 5'SS. In fact, the loss of hnRNP Hl/H1 binding following the introduction of the - 
2G>A substitution is in agreement with the disruption of this binding site: from GGGgu 
to GAGgu. Also, when the sequences of other exons were examined closely, the only 
significant difference between the mutated exon 3 G>C sequence and exons such as 7, 
10b or 37 is represented by the absence of G runs in the vicinity of the 5' SS, suggesting 
that in these exons there is no binding site for hnRNPHl/H'. In this model, only the very 
stable occupancy of Ul snRNP at the wild type 5'SS prevents the hnRNP Hl/H' molecule 
inhibiting complex formation. However, following the +5 G>C substitution Ul snRNP 
occupancy is weakened and the presence of the hnRNP Hl/H’ binding site is removed by 
the -2G>A substitution Ul snRNA-pre-mRNA complex formation is not restored to the 
wild-type condition (because of the +5G>C substitution) but correct splice site 
recognition can again take place (as it evidently does in other very similar donor sites 
such as those in exon of exon 7 and 37).
Therefore data from this project shows that distinct sequence specific protein complexes 
can bind the RNA region surrounding a donor splice site and that in some cases these 
proteins can affect donor site recognition by the splicing machinery. This may be one of 
the reasons why, at the molecular level, nucleotide frequencies are selected on 
additional factors rather than just Ul snRNA complementarity and provides an 
indication that early protein binding events can influence the outcome of later RNA 
processing steps. In addition, considering the evr-increasing need for distinguishing
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innocuous polymorphisms from potential disease-causing mutations this finding 
highlights the need for careful ‘local context’ analyses when predicting the possible 
effects of mutations introduced in donor sites.
7.3 A nonsense mutation that causes skipping of exon 37 in NF1 and definition 
of an exonic splice enhancer.
NF1 exon 37 skipping caused a by premature termination codon (PTC) had been 
previously reported due to the nucleotide substitution C6792A that causes the change 
Y2264X. However, mutations in the same area, such as 6790insTT and 6789delTTAC, 
both of which create PTC’s did not result in the skipping of this exon- Figure 25. It 
seems then that the splicing defect is not due to the presence of PTC but probably to the 
disruption of a cis-acting element necessary for correct splicing such as an exonic 
splicing enhancer (ESE).
ESEs are present in constitutively and alternatively spliced exons, are distinct from the 
splice site sequences and are required for efficient splicing of many exons. ESEs may act 
as binding sites for serine/arginine-rich proteins (SR proteins), a family of highly 
conserved and structurally similar splicing factors.
When NF1 exons 34-38 were inserted into a minigene system and mutagenesis of this 
region performed. The results show that, as hypothesised, even a transitionally silent 
mutation in nucleotide 6792 (C6792T) causes skipping. This observation indicates that 
the nucleotide change itself rather than the creation of a stop codon produces aberrant 
splicing. I also see that a cis-acting element affected by the nucleotide change at position
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6792 is also necessary for the correct splicing of exon 36.
The molecular basis of the function of the exon 37 ESE appears very complex. It is 
possible that secondary structure constraints in addition to potential interactions with 
splicing factors elsewhere in the pre-mRNA are involved in correct processing of exons 
36 and 37.
7.4 Silent mutations that did not affect splicing and a new form of recessive 
cancer syndrome.
Two silent mutations generated by sequence analysis were studied using the minigene 
assay. The first in exon 28 (5172 G>A) in a large NF1 family with various features of the 
disorder and no other sequence variation found. However this sequence change was not 
found to cause skipping of exon 28. It may be that this family have a large deletion that 
cannot be detected by ACSA, and that this sequence variation is truly a polymorphism. 
However, this case was useful as a negative control for the assay.
The second was in exon 6 (846 G>A) in a family that did fulfil NF1 diagnostic criteria 
but also had a more extended phenotype with PNETs in two sisters. The sequence change 
did not cause skipping of the exon. However, further studies showed a nonsense mutation 
in exon 6 of the PMS2 gene, changing the diagnosis completely from NF1 to a new 
cancer syndrome. PMS2 is a post replication DNA repair protein and this mutation 
finding significantly widens the spectrum of disorders associated with mismatch repair 
gene defects, and suggests a new form of recessive cancer syndrome. Care should be 
taken when assessing families with consanguinity, features of NF1 and rare tumours and
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consider this syndrome in the differential diagnosis.
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